Features
Pt. G3 tumors (p<0.001). WWTR1 rearrangements were found in 16/17 (94%) G2, 5/9 (56%) G1, and 1/4 G3 (25%) (p<0.005). Within EHE, both rearrangements were found signifi cantly more frequent in G2 than G1 EHE (p=0.034). IHC was positive for ERG 8/10 (80%), CD31 42/45 (93%) and CD34 31/46 (67%). Death occurred in 11/12 (92%) EA compared to 14/28 (50%) EHE with followup (p=0.015). 4 year survival was signifi cantly worse for EA (11%) compared to EHE (33%, p=0.038). For lung cases, 4 year survival was worse for those with pleural thickening (0%) compared to those without (50%, p=0.049). Conclusions: Epithelioid vascular tumors of the thoracic cavity can be classifi ed as low to intermediate grade EHE and high grade EA. This is supported by our survival data as well as the presence of WWTR1-CAMTA1 fusion in most conventional EHE cases with a rare fi nding of WWTR1 in EA. In the presence of necrosis, nuclear pleomorphism and increased mitotic activity in a tumor that lacks vasoformative features, the differential diagnosis between an EA and a malignant EHE remains arbitrary based on morphology alone. Demonstration of WWTR1 or CAMTA1 rearrangements offers an objective criterion that can help establish the diagnosis of EHE and make the distinction from EA. CD31 and ERG appear to be the most useful vascular IHC markers.
Results: TP63 rearrangement was identifi ed in 2 ADs (synchronous lung tumors from 1 patient). The rearrangement resulted in an inversion of 3q that fused B3GALNT1 to TP63. FISH confi rmed the rearrangement in both tumors. IHC staining for p63 was diffuse (>80% cells+) and p40 was negative. Of the 45 additional ADs, 15 (33%) showed p63 expression in 20-60% of cells; p40 was negative in all cases. No case showed rearrangement of TP63 by FISH. However, extra copies of the intact TP63 locus were seen in all 12 cases, with copy numbers ranging from 3 to 7. Extra copies of TP63 were seen in the p63+ areas while only 2 copies of TP63 were present in the p63-negative (3 of 4 cases scored).
Conclusions:
We have identifi ed a novel chromosomal rearrangement involving TP63 in a p63+/p40-lung AD. Breakapart FISH testing can be used to diagnose this fi nding. IHC for p63 was not specifi c for this rearrangement. Additional copies of the intact TP63 locus also were a common fi nding and correlated with IHC positivity for p63. FISH results suggest that partial positivity for p63 by IHC may refl ect clonal heterogeneity within lung ADs.
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Expression of p63 and p40 in Small Cell Carcinoma of the Lung R Bhatnagar, R Sharma, PB Illei. Johns Hopkins Medical Institutions, Baltimore, MD. Background: Morphologic distinction between small cell carcinoma and squamous cell carcinoma can be challenging especially on small biopsy material, including fi ne needle core biopsies, transbronchial biopsies and on cell blocks of cytologic material. Immunohistochemistry using markers of neuroendocrine differentiation (synaptophysin, chromogranin and CD56) are helpful but can be all negative in a subset small cell carcinoma, particularly in biopsy material. Immunohistochemistry for p63 has been commonly used as a marker of squamous differentiation, however, p63 expression has been described in a subset of lung adenocarcinoma, and in rare cases of small cell lung carcinoma. We have evaluated the role of a novel p40 (p63) monoclonal antibody in distinguishing small cell lung carcinoma from poorly differentiated squamous cell carcinoma. Design: Immunohistochemistry using mouse monoclonal antibodies for p63 (clone 4A4) and p40 (clone BC28) were performed on commercially available tissue microarrays of 69 cases of small cell lung carcinoma. The staining was performed on a fully automated immunostainer using polymer based detection. We have also stained 7 cases of poorly differentiated adenocarcinomas of the lung that have previously been focally positive for p40 using a rabbit polyclonal antibody. Results: Overall, positive p63 staining was observed in 13 of the 69 (19%) small cell carcinomas ranging from strong diffuse staining to scattered positive cells (table 1. ). Moderate to strong tumor staining in more than 5% of tumor cells was observed in 6 cases (9%). In contrast, all 69 cases were negative for p40 using the monoclonal antibody (clone BC28). The 7 cases of poorly differentiated adenocarcinomas showed the same focal staining (with similar intensity) for both p40 antibodies. Conclusions: P63 positivity can be seen in a subset of small cell carcinoma, while no p40 (p63) staining was observed in the same cohort of tumors. Immunohistochemistry for p63 alone should not be used as single marker to exclude squamous differentiation in small cell carcinoma of the lung. The monoclonal p40 antibody showed similar staining characteristics to a commonly used polyclonal antibody in a selected rare cohort of poorly differentiated adenocarcinoma.
as positive if≥70% of tumor cells showed diffuse nuclear and cytoplasmic staining. Punctate nuclear hybridization signals by DNA ISH in the malignant cells defi ned a HPV-positive carcinoma. Results: Of the 199 cases (111 men, 88 women, median age 71 years, range 33-87 years), p16 was positive in 19 ADC and 10 SqCC, but hrHPV DNA ISH was negative in all cases. There is no correlation between positive p16 expression and the following parameters: age, gender, smoking status, tumor size, histologic type, grade and stage. Conclusions: Our study did not detect HPV infection by hrHPV DNA ISH in any of the primary NSCLC despite positive p16 expression in a portion of both ADC and SqCC. P16 should therefore not be used as a surrogate marker for HPV infection in NSCLC.
Frequency of TERT Promoter Mutations in Squamous Cell
Carcinomas of Different Origins K Cheng, J Zhuge, PMR Ravella, R Lafaro, M Zhong. Westchester Medical Center/ New York Medical College, Valhalla, NY. Background: Telomerase reverse transcriptase (TERT) is up-regulated in a variety of human neoplasms and contributes to carcinogenesis. TERT promoter mutations were recently discovered in melanoma by next generation sequencing. Studies have indicated that, these mutations are highly prevalent in melanoma, glioblastoma, and bladder cancers, and low frequency in non small cell lung cancer (NSCLC) cell lines. However, these fi ndings have not yet been illustrated TERT promoter mutation status in squamous cell carcinoma (SCC) of the lung as well as other primary SCC. Our aim was to investigate whether the aforementioned TERT promoter mutations were present in SCC of different origins. Design: Total 53 cases were selected from the archives of our pathology department. These include 24 lung SCC, 12 head and neck SCC, 9 cervical SCC and 8 skin SCC. All Hematoxylin and Eosin (HE) stained slides were reviewed to confi rm the diagnosis and make sure at least >20% tumor content. In addition, several cases of non neoplastic tissue from the matched SCC patient were also studied. Genomic DNA was isolated from FFPE tissue and PCR was used to amplify TERT promoter region which included the C228T and C250T mutations. The TERT promoter mutations are determined by bi-directional Sanger sequencing.
Results:
The TERT promoter mutations were absent in all of the lung SCC and cervical SCC. In head and neck SCC, only two out of twelve (2/12; 17%) cases had the C228T mutation. For skin SCC, four out of eight (4/8; 50%) cases had the mutations including 3 cases of C228T and 1 case of C250T. No mutations were detected in the matched non-neoplastic tissue.
Conclusions: This is the fi rst study to compare TERT promoter mutations in SCC of different origins. In our study, the TERT promoter mutations were not present in any of the lung and cervical SCC. The frequency of TERT promoter mutation is 17% and 50% in head neck SCC and skin SCC, respectively. The fi ndings further illustrate molecular differences among SCC from different origins despite their shared morphologic and immunophenotypic features. The TERT promoter mutations could be of utility as a molecular marker to distinguish SCC with different origins. Background: Lung cancer is the leading cause of cancer-related death in the United States. The identifi cation of recurrent genetic alterations involving EGFR, ALK, and KRAS has revolutionized the clinical management of patients with lung adenocarcinoma. The molecular mechanisms underlying the tumorigenesis of lung squamous cell carcinoma (SqCC), however, are less understood. Alterations of the PIK3CA/AKT pathway have been recently reported in up to 47% of lung SqCC. Given the ongoing development of protein kinase inhibitors as potential therapeutic agents, we evaluated alterations in the PIK3CA/AKT pathway in lung SqCC. Design: Tissue microarrays were constructed from 145 surgically resected lung SqCC specimens (2 cores of each case; 61% in stage 1, 26% in stage 2, 12% in stage 3, and 1% in stage 4). The preservation or loss of PTEN expression was determined by immunohistochemistry. 80 cases were further analyzed by a clinically validated multiplexed PCR based assay to detect specifi c single nucleotide mutations in PIK3CA (8 variants) and AKT1 (1 variant). Correlations between genetic mutations, protein expression, and clinicopathological characteristics were assessed by log-rank and Fisher's exact tests. Results: PIK3CA mutations were identifi ed in 7 (9%) of the 80 specimens. No cases harbored the tested AKT1 mutation. Loss of PTEN expression was found in 25% of the cases and one case had concurrent PIK3CA mutation and PTEN loss. In total, 35% of cases analyzed with both multiplexed PCR and PTEN immunohistochemistry harbored PIK3CA/AKT pathway alterations. These alterations, however, were not associated with specifi c clinicopathological features, including survival.
PIK3CA/AKT Pathway Alterations in Squamous Cell

Conclusions:
A signifi cant fraction (1/3) of lung squamous cell carcinomas harbor alterations in the PIK3CA/AKT pathway Testing of these biomarkers in SqCC may become useful in the future as multiple inhibitors of this pathway are being examined in clinical trials. AW Chi, SE Johnstone, R Heist, E Mark, M Mino-Kenudson. Massachusetts General Hospital, Boston, MA. Background: Although activating KRAS mutations are the most common driver mutations in lung adenocarcinoma of the western population, how KRAS mutations drive tumorigenesis is not completely understood. Several preclinical studies have shown that KRAS mutations suppress a pro-apoptotic protein, BCL2 interacting mediator of cell death (BIM), and subsequently facilitate proliferation. However, little is known about the expression of BIM and other pro-apoptotic and anti-apoptotic proteins in association with clinicopathological characteristics in lung adenocarcinoma. Here, we analyzed the expression of BIM and BCL2, an anti-apoptotic factor, in our molecularly annotated lung adenocarcinoma cohort. Design: Eight tissue microarrays are constructed from 158 surgically resected lung adenocarcinoma specimens (3% stage 0, 72% stage 1, 16% stage 2, and 9% stage 3). All specimens were submitted for multiplex PCR analysis to detect specifi c single nucleotide mutations in multiple genes, including KRAS. The expression of BIM and BCL2 was analyzed using H-score by immunohistochemistry. Appropriate cut-off for positive expression was determined. Correlation between protein expression and genetic mutations, clinicopathological characteristics and survival was assessed by Fisher's exact and log-rank tests.
Evaluation of BCL2 and BIM Expression and KRAS Mutations in Lung Adenocarcinoma
Results: Positive expression of BIM was seen in 53% and 59% of KRAS mutants, 33% and 29% of EGFR mutants and 46% and 53% of tumors without KRAS or EGFR mutations, in the entire and stage 1 cohorts, respectively. BIM expression was more prevalent in the KRAS mutants, especially in the early stage tumors, compared to the EGFR mutants (p=0.017). The expression of BCL2 was limited in our cohort (19%) and there was no correlation between BCL2 expression and molecular alterations. Interestingly, there was a positive association between BCL2 and BIM expression in epithelial cells of lung adenocarcinomas (p=0.036). However, there was no signifi cant difference in the clinicopathological characteristics or survival between BIM+ vs. BIM-, BCL2+ vs. BCL2-, or BIM+BCL2-vs. BIM-BCL2+ tumors. Conclusions: Our study shows counterintuitive correlation between BIM expression and KRAS mutations in resected lung adenocarcinomas, highlighting the complex interactions between pro-and anti-apoptotic molecules. It further suggests possible involvement of other pathways in the KRAS-BIM axis. The absence of correlation between BIM and BCL2 expression with prognosis warrants the need for further investigation of these and other pro-and anti-apoptotic proteins in tumor biology. Background: Molecular alterations commonly associated with lung adenocarcinoma (ACA) are also seen in adenosquamous carcinoma (ASqC). Currently, the diagnosis of lung ASqC requires the presence of both squamous cell carcinoma (SqCC) and ACA components on histologic examination with each comprising at least 10% of the tumor. However, the signifi cance of a minor ACA component (< 10%) in otherwise classic SqCC in association with molecular alterations is not well understood. In addition, the prevalence of lung cancers that are morphologically diagnosed as SqCC but harbor an ACA immunophenotype has not been well documented. Design: A prospective database of resected lung cancers was queried to identify patients with SqCC who underwent primary resection without neoadjuvant therapy since 2005. Of those, cases with the pathology diagnosis made solely by morphology (without ancillary tests), and available tissue blocks (n=154) formed our study cohort. Each case was evaluated for the presence of any glandular differentiation. Mucicarmine stain was used to confi rm the presence of mucin in some cases. Analysis of TTF-1, Napsin A, CK5/6, and p40 expression was performed on tissue microarrays. As part of clinical care at our institution, SNaPshot (a multiplex PCR-based platform for common driver mutations) was also performed in 84 cases.
The Prevalence and Implication of Adenocarcinoma Component in Lung Cancer with Morphological Diagnosis of Squamous Cell Carcinoma
Results:
The 4-marker panel immunohistochemical analysis supports the diagnosis of ACA (with a solid pattern) in 10 tumors (6.5%). Of these, the retrospective review revealed the presence of mucin in 3. The review also identifi ed 12 additional cases (7.8%) with a minor ACA component (<10%). SNaPshot assay was performed in 14 of the 22 cases, and showed KRAS mutations in one of solid ACAs (1/5, 20%) and one of SqCCs with a minor ACA component (1/9, 11%). Interestingly, another case of the latter group harbored an IDH1 mutation. Conclusions: Misinterpretation of ACA with a solid component as SqCC and the presence of a minor ACA component in otherwise classic SqCC (possible ASqC) are not infrequently encountered in lung cancers with morphological diagnosis of SqCC. Given the clinical importance of the distinction, greater emphasis should be placed during morphological evaluation and immunohistochemistry should be applied in any questionable cases to improve the sensitivity for detecting an ACA component.
evaluable (NE) after treatment with EGFR-tyrosine kinase inhibitor (TKI). And there were 7 PR, 2 SD, 1 PD and 10 NE among 20 mutation positive patients by direct sequencing method. The response prediction rate to EGFR TKI was 77.3% by PNA clamping and 70.0% by sequencing (p=0.583).
Conclusions:
These results showed higher detection rate of EGFR mutation by PNA clamping compared with direct sequencing and moderate concordance between two methods. PNA clamping could be more useful screening method for detection of EGFR mutations.
Non-Small Cell Lung Carcinoma Brain Metastases with Squamous
Cell Carcinoma or Small Cell Carcinoma Histology ML Cowan, WH Westra, PB Illei. Johns Hopkins Medical Institutions, Baltimore, MD. Background: Tissue diagnosis of stage IV lung carcinoma is frequently made on biopsies of metastases including solitary brain metastases that are often excised for both diagnostic and therapeutic purposes. The majority of brain metastases have adenocarcinoma (ACA) histology, while a minority can have adenosquamous carcinoma (ADSQ), squamous cell carcinoma (SQC) or small cell carcinoma (SCC) histology. Not infrequently the metastatic tumor remains the only tumor sample available for histologic/molecular analysis. For these minority brain metastases that show ADSQ, SQC or SCC histology, it is not known whether this morphology reliably refl ects the histologic subtype of the primary lung cancer. Design: The archives of our department were searched for patients with brain metastases of SCC, SQC and ADSQ of the lung (1980 to August 2013) who also had their primary tumors sampled. We then compared the reported histologic types of the primary and metastatic tumors and analyzed the lung cancer mutation results if available.
Results: Of 106 patients with metastatic small cell carcinoma in the brain, 11(10.4%) had tissue sampling of the lung primary. Of these, 3 (3 of 11 -34%) showed different morphology in the lung (1 squamous cell carcinoma, 1 adenocarcinoma, and 1 combined adenocarcinoma-small cell carcinoma). Mutation analysis of the latter tumor demonstrated the same KRAS mutation (G12A) in both ACA and SCC component of the lung primary and in the brain metastasis. Of 89 patients with metastatic squamous cell carcinoma in the brain, 9 (11.2%) had lung tissue sampling, and all 9 were SQC (100%). Interestingly, we also identifi ed 5 metastatic ADSQ; 3 with ADSQ primary, 1 with large cell undifferentiated carcinoma primary and 1 with an EBUS mediastinal lymph node biopsy showing SQC. One brain metastasis showed mixed SQC-SCC histology and had a primary mediastinal SCC primary. One of the metastatic ADSQ had an exon 19 (E746_A750del5) EGFR while the mutation status of the others is not known.
Conclusions:
These fi ndings suggest that at least a small subset of patients with non-small cell lung carcinoma present with SCC brain metastasis. The relatively low frequency of these cases raise the question whether mutation studies should be performed on all brain metastasis of suspected lung tumors where the primary tumor is not or sub optimally sampled in order to ensure appropriate therapy. Mutation studies of all these tumors could provide important data to better understand this process.
1955 P D -L 1 E x p re s s i o n i n M a l i g n a n t M e s o t h e l i o m a : A n Immunohistochemical Analysis of 33 Cases ML Cowan, PM Forde, JM Taube, J Brahmer, PB Illei. Johns Hopkins Hospital, Baltimore, MD. Background: Malignant mesothelioma is an aggressive neoplasm with 43,000 deaths worldwide and no effective systemic therapy. Since most mesotheliomas are associated with asbestos exposure and chronic infl ammation they are potentially "immunogenic tumors". Novel immune checkpoint inhibition of programmed death -1 (PD1) targeted therapy has shown promise in other solid tumors including non-small-cell lung cancer (NSCLC) and malignant melanoma. Mesothelioma mouse model data suggest high expression of programmed death-ligand 1 (PD-L1), the lead candidate biomarker of anti-PD-1 therapy but there is no data available regarding expression levels in primary human mesotheliomas. Here we report the rate of PD-L1 expression in malignant mesothelioma and in associated tumor infi ltrating lymphocytes. Design: Immunohistochemistry for PD-L1 (murine anti-human PDL1 monoclonal antibody 5H1) and CD3 (mouse monoclonal antibody, clone PS1) was performed on standard formalin fi xed paraffi n embedded tissue sections of large biopsy or resection specimens of 25 of pleural (17 epithelioid, 7 biphasic  1 sarcomatoid; median age: 65) and 8 peritoneal (all epithelioid, 2 in tunica vaginalis, median age: 72.5) mesotheliomas. Based on earlier published studies tumor cells or tumor infi ltrating lymphocytes were considered positive if at least 5% exhibited membranous staining. The CD3+ tumor infi ltrating lymphocytes (TIL) were estimated as percent of cells within the tumor and the presence and location of lymphoid aggregates as well as percent of PD-L1 positive TIL was also evaluated.
Results:
The tumor cells were PD-L1 negative in 10 cases while positive in 23 cases (1 had 5% staining, 8 had 6-49% staining and 14 had≥50% staining). The majority of tumors exhibited geographic (primarily peripheral zonal) staining but diffuse staining was also noted. PD-L1 positivity was noted in 50% of peritoneal and 76% of pleural mesotheliomas. The majority (83%) of PD-L1 positive tumors also had PD-L1 positive TIL (range of PD-L1 positive TIL: 5-80%) and lymphoid aggregates (74%). TIL were seen less often (40%) in PD-L1 negative tumors (range of PD-L1 positive TIL: 10-60%).
Conclusions:
The majority of malignant mesotheliomas are PD-L1 positive by immunohistochemistry and contain PD-L1 positive TIL. Pleural mesotheliomas are more often positive than peritoneal mesotheliomas (76% vs. 50%). These fi ndings suggest that malignant mesothelioma is potential candidate for anti-PD-1 therapy. OR Elkadi, A Tarasen, LX Foulke, CE Sheehan, K Wang, GA Otto, G Palmer, R Yelensky, D Lipson, J Chmielecki, SM Ali, D Morosini, VA Miller, PJ Stephens, JS Ross was applied to≥ 50ng of DNA extracted from 49 SCLC FFPE tumor specimens and sequenced to high, uniform coverage. Genomic alterations (base substitutions, small indels, rearrangements, copy number alterations) were determined and then reported for these patient samples. Actionable GA were defi ned as those identifying anti-cancer drugs on the market or in registered clinical trials (CT).
Evaluation of Small Cell Undifferentiated Lung Cancer by Next Generation Sequencing Reveals Frequent Consistent Genomic Alterations
Results: There were 31 female and 18 male SCLC patients with a median age 57.5 years (range 32-83 years). All tumors were high grade, and 21 tumors were stage IV, 24 stage III, 2 stage II and 2 stage 1 at time of sequencing. All 49 (100%) of SCLC had GA on NGS with a total of 149 GA were identifi ed for an average of 3.04 GA per tumor with 100% of SCLC cases harboring at least one alteration. The most common non-actionable genomic alterations were alterations in TP53 (71%), RB1 i (67%) and MLL2 (16%). Twenty one (43%) of cases harbored at least 1 actionable GA including mutation, amplifi cation or homozygous deletion in EGFR (6%), PIK3CA (6%), PTEN (6%), RICTOR (6%), TSC1 (6%) and
Conclusions: More than third of the patients harbored at least one actionable GA. The long tail of altered genes and multiple mechanisms of alteration necessitate broad diagnostic assays from limited biopsy material to maximize targeted therapeutic options in an individual patient. Given the limited treatment options and poor prognosis of patients with SCLC, comprehensive NGS-based genomic profi ling has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease.
S OX 2 Expression in EGFR and KRAS Mutated Lung Adenocarcinomas
Emory University Hospital, Atlanta, GA. Background: SOX2, is a transcription factor associated with maintaining the pluripotency and self renewal capacity of embryonic stem cells. It is preferentially amplifi ed in lung adenocarcinomas from never smokers, may be an adverse prognostic marker. SOX2 is also a key downstream target of EGFR signal, but can be down regulated in a murine model of KRAS induced lung adenocarcinoma. Herein we investigated SOX2 expression in a set of lung adenocarcinomas with and without mutations in a set of key oncogenes. Design: Based on previous reports, nuclear staining for SOX2 (goat polyclonal, RD systems) was scored as positive or negative using a 5% cutoff. Tumors were assessed for point mutations by multiplexed PCR, single primer extension, and capillary electrophoresis. PCR amplifi cation and capillary electrophoresis based size assessment were used to determine the presence of insertions and deletions in EGFR and HER2. Results: Of the 29 cases analyzed, 87.5% (14; n=16) of the cases with mutations and 92.3% (12; n=13) without mutations were SOX2 positive. Of the SOX2 positive cases with mutations, 100% of the EGFR (6), BRAF (2) and Her2 (1) mutated cases were SOX2 positive while 71.4 % (5, n=7) of the KRAS cases were positive. Conclusions: SOX2 is expressed in lung adenocarcinomas with EGFR, BRAF and Her2 mutations, but may not be expressed in KRAS mutated adenocarcinomas, raising the possibility that not all KRAS mutated tumors utilize SOX2 mediated cancer cell renewal. Mutations KE Fisher, N Fatima, RR Micahael, Z Linsheng, K Sungjin, C Zhengjia, OK Taofeek, RS Suresh, K Fadlo, GA Anthony, SL Gabriel . Emory University School of Medicine, Atlanta, GA. Background: TRU lung adenocarcinomas that recapitulate the lung alveolar and non ciliated bronchiolar epithelium are associated with activating mutations in the tyrosine kinase domain of the EGFR gene. However, not all TRU adenocarcinomas harbor mutations in the EGFR gene and the genomic profi le of non-TRU adenocarcinomas have not been well defi ned. We investigated differences in the genomic profi le of TRU and non-TRU lung adenocarcinomas and assessed for associations between these two morphologic subtypes and genomic characteristics. Design: We classified lung adenocarcinomas using the previously published morphologic criteria for TRU and non-TRU. Cases that were not classifi able into either group were coded as mixed. Point mutations were assessed by multiplexed PCR, single primer extension, and capillary electrophoresis. Insertions and deletions in EGFR and HER2 were determined by PCR amplifi cation and size assessment after capillary electrophoresis. Univariate association between the mutation status and TRU and non TRU histology was examined with Fisher's exact test using SAS 9.3 (SAS Institute, Inc., Cary, North Carolina) with a signifi cant level of 0.05. Results: There were 41 cases of lung adenocarcinoma and 1 case of adenosquamous carcinoma included in this analysis. Sixteen cases were classifi ed as TRU, 22 as non-TRU and 4 as mixed. EGFR mutation was detected in 6 of 42 informative cases (14.2%) while KRAS mutation was present in 7 of 29 informative cases (24.1%). 10.3% (n=3) of 29 cases had activating mutations in other oncogenes, including a deletion in Her2 and point mutations in BRAF. KRAS mutation was more frequent in non-TRU vs TRU adenocarcinomas (42.9% vs. 7.7%; p=0.077) while non KRAS mutations, including EGFR, were more likely to occur in TRU adenocarcinomas (53.9% vs. 7.1%; p=0.013). Conclusions: Non-TRU adenocarcinomas are more often associated with KRAS mutation, while TRU adenocarcinomas are more often associated with non KRAS mutations, including EGFR, Her2 and BRAF. The correlation of morphologic subtypes of lung adenocarcinoma with distinct driver genomic alterations suggests a fundamental difference in the morphologic and genomic evolution of these histologically divergent tumor subtypes.
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Organizing Pneumonia and Smooth Muscle Proliferation Is a Frequent Histopathologic Finding in Grossly Normal Areas of Lungs Explanted for Usual Interstitial Pneumonia DJ Fix, J Collins, AP Burke. University of Maryland Medical Center, Baltimore, MD. Background: The histologic fi ndings of uninvolved lung parenchyma in patients with UIP requiring lung trasnplantation has not been well studied. Our goal is further describe these fi ndings based on histologic patterns and immunohistochemical staining. Design: We prospectively studied 19 single lung transplants for UIP, and sampled 4 (in most cases) grossly normal areas from all lobes. There were 18 men and 1 women, 14 right and 5 left lung transplants. Sagittal sections were performed after infl ating with formalin fi xative, and gross photographs taken in each case. Histologic features of OP were described by location as interstitial, paraseptal, or peribronchiolar. Immunohistochemical staining for anti-smooth muscle actin antibody (SMA) and antidesmin antibody (DES) was performed on all sections, and patterns of staining regarded as 'above normal levels', as well as categorized by basic histologic patterns defi ned as: Interstitial and Nonspecifi c interstitial pneumonitis-like (NSIP-like) (positive for SMA, with rare focal areas of desmin positivity), areas of OP (positive for SMA with variable DES staining), and nodular proliferations with smooth muscle hyperplasia (positive for both SMA and DES). Results: Of the 73 sections examined, OP-like areas were present in 57 (78%), with all lungs containing at least one focus. There were 230 foci of OP in total, with 136 interstitial (59%), 73 paraseptal (32%), and 21 peribronchiolar (9%). There were numerous foci of chronic interstitial pneumonitis with areas of infl ammation and fi brosis and abundance of SMA positive cells suggestive of a NSIP-like pattern, identifi ed in 17/19 (89%) of cases comprising 5-100% of tissue present. Immunohistochemical staining patterns were observed as follows: Interstitial/NSIP-like in 15/19 (79%), OP-like areas in 11/19 (58%), nodular proliferations with smooth muscle hyperplasia in 6/19 (32%) of cases.
Conclusions: Normal areas in UIP lungs frequently exhibited areas of OP, NSIP-like changes, as well as nodular proliferations of smooth muscle hyperplasia in a lesser but signifi cant proportion. Underlying these changes are increases in SMA and DES in reproducible patterns.
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Identification of Novel Somatic Variants in Thymic Epithelial Tumors by Next-Generation Sequencing J Fujimoto, J Zhang, CR Pickering, H Kadara, C-G Liu, JA Drummond, DM Muzny, H Doddapaneni, A Weissferdt, DA Wheeler, JN Myers, J Wang, II Wistuba, N Kalhor, CA Moran. The University of Texas MD Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX. Background: Thymic epithelial malignancies mainly comprise thymomas and thymic carcinomas and represent about 1% of all epithelial tumors. Our knowledge on the molecular makeup and pathogenesis of thymic tumors is substantially lacking. In this study, we sought to characterize exonic mutations in a limited set of thymic tumors by next-generation sequencing (NGS). Design: We performed whole-exome sequencing of 5 frozen paired thymic tumors (3 thymomas and 2 thymic carcinomas) and adjacent normal tissues using the Illumina HiSeq 2000 platform. Exon capture was performed using the Nimblegen exon capture array. Variants that were detected in normal tissue, silent and reported in dbGAP and 1000 genomes were fi ltered out to identify somatic exonic non-synonymous alterations. Top calls were then selected based on involvement in known cancer-related pathways. Identifi ed top somatic variants were analyzed and confi rmed in 22 formalin-fi xed paraffi n embedded (FFPE) epithelial rich thymic tumors 14 thymomas and 8 thymic carcinomas) by Ion Torrent sequencing using the PGM platform on Ion 318 chips and the AmpliSeq comprehensive cancer panel. Select variants were then visualized by the Integrative Genomics Viewer (IGV) software. Results: We identifi ed, using whole-exome sequencing, candidate somatic alterations in 59 genes comprised of 1 frame shift insertion, 8 deletions as well as 50 single nucleotide variants (SNVs). The highest number of somatic alterations per tumor was 27 (in a thymic carcinoma). Top variants included a missense mutations in harvey rat sarcoma viral oncogene homolog (HRAS), carbonic anhydrase 6 (CA6), guanine nucleotide binding protein alpha 11 (GNA11), jumonji AT rich interactive domain 2 (JARID2) and a deletion in the multiple endocrine neoplasia 1 (MEN1). Additionally, we identifi ed using a more conserved base calling approach SNVs in ataxia telangiectasia mutated 1 (ATM) and neurofi bromin 1 (NF1) tumor suppressors. Notably, Ion Torrent sequencing confi rmed exonic somatic mutations in the HRAS oncogene (2 thymomas) and ATM tumor suppressor (1 thymoma) and identifi ed an additional somatic alteration in NRAS in a thymoma. Conclusions: Our whole-exome and targeted NGS analyses identifi ed previously uncharacterized somatic alterations in a limited set of thymic tumors and point to potential activation of RAS oncogenes in the pathogenesis of this rare epithelial malignancy. Current efforts are underway to analyze a larger set of thymic tumors by NGS. Carcinoma F Galateau Salle, N Le Stang, M Grimaux, V Leon, K Kampbell, Y Oulkhouir, S Lecot Cotigny, E Bergot, G Zalcman. UMR1086 INSERM, Caen, Noormandy, France; UMR1086, Caen, Noormandy, France. Background: Fibroblast growth factor receptor 1 (FGFR1) gene amplifi cation has been recently reported in 10 to 20% of primary squamous lung cancer(SCC). To date, it is the main actionable molecular target occurring in lung SCC. Whether FGFR1 amplifi cation could help to select patients for specifi c FGRF tyrosine kinase inhibitors remains unknown. The aims of this study is to assess the actual frequency of FGFR1 amplifi cation in a series of SCC consecutive patients, from a University Hospital with clinical, demographic characteristics and smoking exposure correlations. Design: 82 SCC were identifi ed from the charts of the thoracic oncology Department of Caen University Hospital. For all patients medical records, demographic characteristics, smoking history, treatment details were collected from march 2005 to February 2013. All cases were tested for FGFR1 FISH analysis using the FISH Zytolight SPE FGFR1/ CEN8 DUAL color probe on paraffi n embedded tumor tissue. Amplifi cation was positive when the ratio was>2.2. The variables were compared with bilateral exact Fisher and with Mann-Whitney tests. Results: Among 82 SCC patients, 85% were male,15 % female, median age 63 years. Current smokers were 45%, former smoker 54%, never-smoker 1%, with an average of 40 Pack/years. WHO PS 0/1/2 patients were respectively 31%, 45%, and 24%. Stage IV patients were 63%. FGFR1 FISH amplication was observed in 13.5% of cases. There was no signifi cant statistical difference between sex, age, smoking history and metastatic versus limited stage. While patients with SCC are current or former smokers there was a slight trend of FGFR1 amplifi cation in light smokers/ex smokers . In stage IV patients, PFS did not signifi cantly differ according to FGFR1 status possibly refl ecting a lack of power. Conclusions: Our study shows 13.5% of FGFR1 amplifi cation in primary SCC lung cancer and should be systematically tested for their putative predictive value when FGFR TKIs will be available. PFS/OS data will be up-dated and presented at the meeting. Background: Thymomas are rare tumors arising from the epithelial cells of the thymus gland. The current WHO classifi cation categorizes these tumors in to 2 main types, type A (or Spindle) and type B (or polygonal) based on the nature of the epithelial cells. The latter is further subcategorized into B1, B2, and B3 based on the cellularity and atypia of the epithelial component. The goal of the current study was to analyze the importance of the subclassifi cation of type B thymomas in relation to behavior of the tumors. Design: Eighty-seven cases of type B thymomas that were seen in our tertiary referral center (in-house and referral cases) for thymic carcinomas and were reexamined by a single pathologist. Clinical data was obtained from our database and correlations were performed with stage of presentation, likelihood of residual disease, distant metastasesfree survival, and likelihood of being free of disease at the end of the followup period. Chi-square test was performed to analyze the statistical signifi cance. Results: Histological classifi cation showed that the series consisted of 18 B1, 31 B2, and 38 B3 thymomas. The followup period ranged from 1 month to 21 years (median, 5.2 years). There were no signifi cant differences in the age at diagnosis, presence of autoimmune disease, stage at presentation (stage I/II vs stage III/IV), or likelihood of residual disease after surgery. There were also no signifi cant differences in the likelihood of development of metastases (at 3 or 5 yrs) or being alive without disease for B1, B2, and B3 tumors. The survival results were similar when the analysis was performed using 2 categories (B1+B2 vs B3 or B1 vs B2+B3) instead of 3 categories. Conclusions: The data suggest that there are no signifi cant differences in the biological characteristics of subtypes of thymoma type B. In view of the unexpected results, we are expanding the study to all the cases of type B thymomas (350) at our institution. Provided the results are confi rmed, they challenge the current paradigm and will necessitate a major reconsideration of the classifi cation of these tumors. Background: Malignant Mesothelioma (MM) is a tumor with dismal prognosis, often associated with exposure to asbestos. MM cases have also been reported in familial clusters and in patients previously treated for cancers such as breast cancer, renal cell carcinoma and melanoma. BAP1 a tumor suppressor gene located on chromosome 3.p21 shows mutations/insertions or LOH in numerous cancers. We have analyzed the correlation between BAP-1 genetic alterations and immunohistochemistry (IHC) in a series of pleural MM (PMMs) associated with and without history of other cancers. Design: A total of 159 strictly ascertained PPMs were selected from the MESOPATH (French mesothelioma study panel). This series included 83 PMM cases with previous history of cancer (PMM-cancer-group: 67 breast cancer, 7 renal cell carcinoma and 8 melanoma 1 with breast and melanoma) and 76 PMM cases without previous history of cancer (PMM-no cancer group). BAP-1 nuclear staining (BAP1-NS) was detected using anti BAP1 (clone C-4, from Santa Cruz). BAP-1 was scored as positive or negative. Genetic alterations were analyzed in a subset of 33 PMM cases (24 MMS with cancer and 9 without previous cancer). DNA from PMMs was amplifi ed by PC (exon 1 to exon 17) and amplifi ed products were analyzed by direct sequencing. Survival was evaluated with Kaplan Meier analysis and log rank tests. Results: A total of 110/ 159 cases were negative for BAP-NS with a tendency for a lower proportion of negative in the PMM-cancer versus PMM-no cancer group (60% vs 79%, p=0.001). BAP1 gene alterations were detected in 10/20 BAP1-NS negative cases, and in 0/10 BAP1-NS positive cases, no difference between PMM-cancer and PMMno cancer groups. Gene alterations included 7 mutations and 3 deletions/insertions. Negative BAP1-NS was associated with a trend to a worse prognosis (median overall survival 14 months in BAP1-NS negative versus 19 months in BAP1-NS positive cases). Conclusions: Loss of BAP-1-NS might predict worse prognosis of PMM. About 50% of BAP1-NS negative harbor BAP-1 gene alteration. Thus, BAP-1 IHC is not predictive of mutation status, although no false positive (i.e BAP-1-NS positive with BAP-1 mutation) is observed. Patients with previous history of cancer tend to be more frequently negative for BAP-1-NS.
FGFR1 Gene Amplification in Squamous Cell Bronchopulmonary
BAP1 Sequencing and Immunohistochemistry in a Series
Clinicopathologic Features of Granulomatous-Lymphocytic
Interstitial Lung Disease (GLILD) vs. Sarcoidosis F Hamadeh, D Culver, C Farver. Cleveland Clinic, Cleveland, OH. Background: Patients referred to our Sarcoidosis Center receive an alternate diagnosis in 17% of the cases after the pathology is reviewed. One such alternative diagnosis is granulomatous-lymphocytic interstitial lung disease (GLILD). This is an interstitial lung disease (ILD) that has been described in a subset of patients with common variable immunodefi ciency (CVID) and has pathologic features that can overlap signifi cantly with those of sarcoidosis. We conducted a histopathologic comparison between a group of patients with documented GLILD arising in the setting of CVID and a matched group of patients with sarcoidosis. Design: Cases histologically and clinically suspicious for GLILD were reviewed from the authors' case fi les. 8 cases consistent with GLILD and 8 cases of pulmonary sarcoidosis were identifi ed and HE slides from pulmonary specimens were reviewed. Tissue stains for microorganisms (Grocott methenamine silver -GMS-for fungus and Ziehl-Neelsen acid fast -ZN/AFB-for mycobacteria), immunohistochemical stains (CD3, CD4, CD8, CD20 and HHV-8) as well as in situ hybridization for EBV were performed. Whole slide imaging (WSI, Aperio AT scanner) and a Positive Pixel Count Aperio Algorithm were used to estimate the percentage of tissue B and T lymphocyte and CD4 and CD8 T lymphocytes in GLILD and sarcoidosis. Results: Pulmonary tissue sections from GLILD cases showed more prominent interstitial infl ammation with increased areas of organizing pneumonia when compared to the pulmonary sarcoidosis cases. In addition, the granulomas in both GLILD and sarcoidosis cases were non-necrotizing. However, the GLILD granulomas were not in a lymphatic distribution as seen in sarcoidosis, and were more loosely formed. Special stains for microorganisms (GMS and ZN-AFB), immunohistochemistry for HHV-8 and in situ hybridization for EBV were negative in both groups. The difference in tissue CD3:CD20 lymphocyte ratio and the CD4:CD8 ratio between the two groups was not statistically signifi cant.
Conclusions:
The histopathologic features that distinguish GLILD from sarcoidosis include a brisk interstitial infl ammatory infi ltrate with areas of organizing pneumonia and more loosely formed non-necrotizing granulomas. Immunohistochemical stains for B and T lymphocytes and their subsets reveal no signifi cant difference in the ratio of these lymphocytes in GLILD and sarcoidosis. Other risk factors include exposure to the SV40 virus, as well as genetic abnormalities such as the BAP-1 mutation and homozygous 9p21 deletion. Recently, a 56 year old patient with peritoneal mesothelioma and Lynch syndrome was reported in the literature. Additionally, the patient had right-sided colon adenocarcinoma and multiple skin and nasal sebaceous carcinomas. His family history was positive for 1 st degree relatives with colon cancer. His mesothelioma exhibited loss of mismatch repair (MMR) proteins MLH1 and PMS2 by immunohistochemical (IHC) staining. Mutational analysis revealed a deleterious germ-line mutation in MLH1. In this study, our intent was to determine the prevalence of MMR protein loss in our mesothelioma patient population. We also aspired to correlate these results with relevant clinicopathologic features. Design: From January 1991 to April 2013, we identifi ed 37 patients with malignant mesothelioma in our database. Their average age was 67 (range 45-88). There was a predominance of males (33, 89%). Thirty-two (86%) of these tumors originated in the pleura, whereas 5 (14%) were peritoneal. Twenty-six (70%) were of epithelioid histology, and 10 (27%) sarcomatoid. Their slides were reviewed, and tissue microarray blocks were constructed. IHC staining with antibodies against MLH1, PMS2, MSH2, and MSH6 was performed, and then confi rmed on pertinent whole slide sections. Results: All 37 of our mesothelioma cases retained MSH2 and MSH6 staining. Two (5.4%) of the cases demonstrated loss of MLH1 and PMS2 expression ( Results: Eleven samples were negative for HR-HPV by the genotyping assay; the extracted DNA from the remaining three cases was not suitable for amplifi cation. Thirteen of 14 SCLC showed strong and diffuse nuclear and cytoplasmic p16 overexpression; one was negative. The pTNM stages of the tumors were: IA (5), IB (2), IIB (2), IIIA (4), and IV (1). Conclusions: HR-HPV genotypes were not detected in any of the 11 SCLC specimens successfully tested, while p16 was up-regulated in 13 of 14 (93%). p16 up-regulation can be used as a surrogate marker of HPV genome integration due to Rb pathway interruption by HPV oncoprotein E7. However, the Rb pathway is known to be inactivated by other mechanisms in SCLC such as p53 mutations or 17p deletions also leading to up-regulation of p16. In conclusion, our fi ndings indicate that unlike some other small cell neuroendocrine carcinomas, the pathogenesis of SCLC does not appear to be associated with HR-HPV infection.
Intra-Tumor EGFR Mutation Status Heterogeneity in Lung Adenocarcinoma Is Associated with Reduced Survival D Hershkovitz, E Simon, E Prinz, T Shentzer, L Chekinsky, E Sabo, O Ben-Izhak.
Rambam Health Care Campus, Haifa, Israel; Technion -Israel Institute of Technology, Haifa, Israel. Background: Current EGFR mutation detection methods in the management of lung adenocarcinoma indicate the presence or absence of specifi c mutations; however, none of these methods identify variables such as intra-tumor heterogeneity (ITH) and mutated allele imbalance (MAI), which might have potential relevance to treatment decisions and prognosis. In the present report we describe a molecular morphometric approach that can identify MAI and ITH in clinical samples. This approach was utilized on a subset of lung adenocarcinoma cases. Design: DNA was extracted from 314 surgical specimens of lung adenocarcinomas and was scrutinized for EGFR mutation. Thirty EGFR mutation positive cases, presented herein, underwent deep sequencing to determine the relative fraction of mutated EGFR copies. Additionally, for each case, a pan-cytokeratin stained slide was scanned at high resolution and analyzed by a pathologist with the assistance of computerized morphometry software to determine the fraction of tumor cells in the area used for DNA extraction. Tumor cells fraction and the fraction of mutated DNA copies were used to identify the presence of ITH or MAI, which were further correlated with patients' clinical and histopathological variables. Results: Of the 314 cases analyzed, 100 screened positive for EGFR mutations. In the 30 EGFR mutation positive cases presented herein, the median tumor cell fraction in the areas used for DNA extraction was 43% (7-78%) and the median fraction of mutated DNA copies was 34% (8-96%). Four cases (13%) showed ITH determined by the presence of less mutated DNA copies than expected from the tumor cell fraction analysis. Ten cases (33%) showed mutated allele copy gains of up to 88 fold. Signifi cantly reduced survival times were noticed in the patients with ITH group with only 50% of the patients surviving longer than 30 months from diagnosis (median survival time: 30) compared to the other patients (89% surviving longer than 43 months, median survival time has not been reached), P=0.02 (Log-Rank test). Background: Accurate sub-classifi cation of NSCLC is essential for therapy and performance of appropriate molecular studies. While Napsin-A, TTF1, and p40 have been used individually in the subtyping of NSCLC, the 3 have never been studied in cocktail form. We evaluated the utility of a novel, triple cocktail (comprised of TTF1, Napsin-A, p40 [TNP] ) in the subclassifi cation of 36 resected NSCLC. Design: A retrospective review of previously diagnosed NSCLC resections yielded 36 total cases which were randomly sorted and double-blinded before review. Clinicopathologic data were also examined. The triple antibody cocktail (brown nuclear stain, TTF; red nuclear stain, p40; and red granular cytoplasmic stain, Napsin-A) was applied to a single representative tumor slide. 2 reviewers (KH, SC) independently confi rmed staining and classifi ed tumors. Discrepant cases were stained separately with p63, CK5/6 and TTF-1. Results: 29 of 36 cases (80.6%) showed correlation with original diagnosis; 16 of 18 (89%) adenocarcinomas (ADC) were TTF/Napsin-A positive (+); 2 (11%) mucinous ADC were TTF/Napsin-A negative (-); 13 of 14 squamous cell carcinomas (SCC) were p40(+); and 1 SCC was p40 (-) but p63(+). No ADC was misdiagnosed as SCC and vice versa. Four (11%) of the original NSCLC cases were reclassifi ed as large cell carcinoma (3) and SCC (1).
Diagnostic Assessments of NSCLC Resection diagnosis** TNP classifi cation** ADC 13 16 SCC 11 13 NSCLC, NOS 12 7* ADC, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC, nonsmall cell lung carcinoma, TNP, TTF1/Napsin-A/p40; * includes 2 TNP(-) ADC and 1 TNP(-) SCC; ** independent assessment by 2 reviewers (KH, SC)
Conclusions:
The novel TNP triple antibody cocktail accurately subclassifi es NSCLCs in the majority (92%) of cases and requires only a single slide for preparation. This methodology may improve tissue availability for molecular testing without sacrifi cing diagnostic accuracy. DH Hwang, Y Jia, E Garcia, A Perry, F Kuo, LM Sholl. Brigham and Women's Hospital, Bost, MA; Utah Valley Regional Medical Center, Provo, UT. Background: Large cell carcinoma (LCC) lacking squamous or neuroendocrine differentiation is clinicopathologically indistinguishable from solid adenocarcinoma (ADC) and is frequently grouped in the ADC subgroup for the purposes of molecular triage and therapy. LCC/solid ADC is strongly associated with a smoking history and harbors a high (40%) frequency of KRAS mutations. The majority of LCC/solid ADC, however, lack one of the commonly queried oncogenic driver alterations (including EGFR, ALK, KRAS), thus therapeutic options are limited for patients with this tumor type. This study aims to clarify the mutational spectrum of LCC/solid ADC and to determine the frequency of possible therapeutic targets. Design: Targeted next generation sequencing (NGS) was performed using a cancer genomic assay to detect mutations, copy number variations (CNVs) and structural variants. The assay captures exonic sequences of 275 cancer genes and 91 introns across 30 genes for rearrangement detection. DNA was isolated from formalin fi xed paraffi n embedded whole tissue sections containing at least 20% tumor nuclei and analyzed by massively parallel sequencing using a solution-phase Agilent SureSelect hybrid capture kit and an Illumina HiSeq 2500 sequencer. MuTect and GATK (Broad Institute) were used to detect single nucleotide variants and indels. VISCAPCancer and CCOPY were used to detect CNVs. Results: 18 LCC/solid ADC known to be KRAS, EGFR and ALK wild type were studied. The median number of mutational events was 10 (range 2-65). On average, 79% of mutations were transversions. 17/18 (94%) cases had TP53 mutations or copy loss. 44% of cases had a clinically targetable oncogenic alteration including HRAS (n=1), NRAS (n=1), PIK3CA mutations (n=3) and MET amplifi cation (n=3). 5/18 (28%) of cases contained deleterious alterations in STK11. Four highly mutated tumors (20 substitution variants) lacked common alterations other than TP53 mutations. Conclusions: Consistent with prior reports, this smoking-related lung tumor type contains a high frequency of transversion mutations. MAPK, PI3K, MEK, and MET pathway alterations are common, suggesting that patients with wild type LCC/solid ADC by standard clinical testing practices may be candidates for ongoing trials of MEK, PI3K and MET inhibitors. A subset of LCC/solid ADC have an unusually high mutation rate; further investigation to identify a unifying mechanism such as a DNA repair defect is needed. [Peifer et al., 2012] . MYC protein expression was recently demonstrated to refl ect underlying MYC pathway activation in lymphomas. Thus, we hypothesize that immunohistochemistry (IHC) for MYC protein overexpression could identify SCLC with MYC pathway activation and that this expression would correlate with gene amplifi cation. Design: 51 cases of SCLC were retrieved from departmental archives between the years 1999 and 2013. Diagnoses were confi rmed following review of HE and IHC for synaptophysin, chromogranin, and Mib-1 if needed. IHC for MYC (clone Y69, Abcam) was performed with nuclear staining scored as follows: 0 absent, 1+ (<25% of cells positive), 2 (25% to 75%), 3 (>75%). MYC copy number (CN) was assessed by dual color chromogenic in situ hybridization using probes to the MYC locus and Chr8 (Ventana Medical Systems, Inc., Tucson, AZ). MYC CN was scored by evaluating 50 cells for signals/cell for both the MYC locus and Chr8 probes. Cases were classifi ed as CN gain for scores of 3 MYC signals/cell or more, and as amplifi ed for scores of 6 signals/cell or more. Results: MYC protein expression was absent in 19, 1+ in 9, 2+ in 2, and 3+ in 5 cases. The number of CISH MYC signals per cell ranged from 1.5 to >15, with average counts as follows: IHC negative (2.61), score 1 (2.23), IHC score 2 (3.63), IHC score 3 (9.72). 18 cases failed CISH analysis, typically due to crush artifact. CISH for MYC CN correlated with IHC for MYC protein expression (Spearman's =0.41, p =0.02). MYC copy gain, including due to polysomy of Chr 8, was seen in 10/33 (30%) cases by CISH. Amplifi cation, present as either homogenously staining regions or double minutes, was seen in 3/33 (9%) cases. Conclusions: By in situ hybridization, MYC amplifi cation was identifi ed in 9% of SCLC and correlated with strong protein expression. This frequency is higher than previously reported and may refl ect the tendency of sequencing-based assays to underestimate copy number changes due to benign stromal contamination and tumoral heterogeneity. As novel MYC-targeted therapies develop, CISH and IHC should be considered as tools for identifi cation of MYC pathway dysregulation. J Iqbal, KL Lim, SK Sai, E Chen Xueqin, L Oon, LK Hon, D Tan . Singapore General Hospital, Singapore, Singapore; National Cancer Center Singapore, Singapore, Singapore. Background: Epidermal growth factor receptor (EGFR) mutation analysis by Sanger sequencing is part of routine clinical practice. However, single-base primer extension and analysis of extension products by matrix-assisted laser desorption/ionization-time of fl ight mass spectrometry (MALDI-TOF) or Sequenom assay (SA) has been used for somatic mutation analyses. Our objective was to assess suitability of SA to detect EGFR mutation in formalin fi xed paraffi n embedded (FFPE) material and cytology samples of lung adenocarcinoma patients compared to widely used Sanger sequencing (SS). Design: DNA was extracted from 31 archival excision FFPE samples and 17 cytology samples with known EGFR direct Sanger Sequencing results. Six of cytology cases had concurrent biopsy tissue. Cellblocks were prepared from the remaining 11 cases. Five and 10 sections (10μm) were cut from cell blocks and biopsy tissue respectively for DNA extraction and subjected to Sanger sequencing. DNA sample concentration and purity were measured using the Nanodrop 2000 spectrophotometerEGFR mutation studies were performed using Sequenom MassArray System (OncoCarta™Panel v1.0). Results: From the 31 excision samples, 26 had concordant results on the Sequenom OncoCarta v1.0 panel: 12 concordant samples were positive for EGFR E746_A750del and 11 concordant samples were positive for EGFR L858R. One concordant sample showed both EGFR L747_S752del and T790M mutations. Two samples were negative on both SS and SA. Of the discordant group, two cases positive for EGFR mutations by SS were negative on SA. Three cases negative on SS showed one EGFR mutation and two K-ras mutations on SA. Interestingly, 25 samples showed multiple mutations on SA. In the cytology group, concordance rate was 90%. EGFR mutations were detected in 6/11 cases with SS from DNA extracted from cell blocks. Using ThinPrep DNA, mutations were detected in 4/6 cases by SA in this group. Two of six cases with concurrent biopsy tissue showed EGFR mutation by SA were confi rmed on the ThinPrep remnant DNA using SA. The two samples that were negative on SA lacked specifi c primers for the corresponding mutations detected in SS. However, SA identifi ed several non-EGFR mutations (K-ras) in these samples. Conclusions: Our study demonstrates the feasibility of Sequenom assays in EGFR mutation analyses in both FFPE and cytology specimens. Due to ability of this platform to profi le multiple somatic mutations in parallel, use of Sequenom may be considered in high volume laboratories. Design: To date, 78 NSCLC cases (50 cytology specimens, 14 small biopsies, and 14 excisions) have been tested using the 50 gene AmpliSeq Cancer Hotspot Panel v2. Briefl y, DNA was extracted from unstained FFPE slides with a minimum tumor cellularity of 10%. DNA was quantifi ed using the PicoGreen method. Barcoded libraries were prepared using up to 10ng of DNA; sequencing was performed on the Ion Torrent PGM (318 chip). Variants were identifi ed using the Ion Torrent Variant Caller Plugin (v3.6.59049) and reference genome hg19. Golden Helix's SVS software v7.7.3 was used for annotation of the variants, as well as prediction of the signifi cance of the variants. Results: Up to 15 samples were run simultaneously on the 318 chip. The PGM provided a minimum of 100x coverage with the majority of amplicons having >500x coverage. All variant calls were initially fi ltered to remove non-coding and synonymous mutations. Golden Helix was then used to annotate variants and help predict pathogenicity. All reported variants received suffi cient coverage and were of high enough frequency to be annotated as true variants. Only 3 cytology samples failed QC due to low DNA concentrations. Of the remaining 75 samples, 14 were wild-type, 31 had one and, 30 had two or more clinically relevant mutations. The most frequent mutations identifi ed were in the following genes (% of cases with mutation): TP53 (33%), KRAS (24%), EGFR (20%), STK11 (9%) and MET (8%). Mutations in 17 additional genes were seen in 1-3 cases, each. Conclusions: The Ion Torrent Ampliseq technology can be successfully performed on small biopsy and cytology specimens, requires very little input DNA, and can be readily applied in clinical laboratories for genotyping of NSCLC. Background: Genetic alterations of chromatin remodeling subunits have been widely reported in a variety of cancers and are thought to mediate tumorigenesis through mis-regulation of gene expression networks. Arid1A and Brg1, two well characterized chromatin remodeling subunits, have been reported to be mutated in multiple tumor types, however the exact incidence of their disruption in squamous cell carcinoma (SqCC) of the lung is not clear. It is also not understood how these mutations relate to other classical genetic alterations in SqCC of the lung. Design: A prospective database of resected lung cancers was compiled of patients with SqCC who underwent primary resection without neoadjuvant therapy between 2005 and 2010. Of those, cases with available tissue blocks (n=97) formed our study cohort. Immunohistochemical stains for Arid1A, and Brg1 were performed on tissue microarrays representing these cases. These data were then compared with clinical data including survival and genetic data querying 84 genes that was obtained as part of routine clinical care, and the results of PTEN expression examined on the tissue microarrays. Results: A small subset (8 of 97 cases) of SqCC lost either expression of Arid1A or Brg1. No case harbored loss of both factors. Loss of either Arid1A or Brg1 in SqCC is associated with a later stage presentation and worse 5 year survival compared to no loss (23% vs 72% p = 0.192), however, the difference did not reach a statistical signifi cance likely secondary to small sample size. Also, in cases with loss of Arid1A or Brg1, no mutation in PI3K or AKT, or loss of PTEN expression was observed. Conclusions: While only a small subset of SqCC cases harbor loss of Arid1A or Brg1, this group appears to have unique clinical behavior in terms of clinical presentation and survival. Additionally, the data presented here suggest that Arid1a and Brg1 may be acting through a distinct biological pathway since their disruption does not occur in tumors carrying PI3K/AKT pathway alterations. Further exploration of the role of these factors in SqCC is warranted given both their prognostic and biological potential. Background: Polytetrafl uoroethylene (PTFE, Tefl on) is a widely-used, chemically stable fl uorocarbon polymer. Pyrolysis products of PTFE have induced "polymer fume fever" in the industrial workers.To date, there have been no reports of chronic pulmonary granulomatosis associated with long termexposure to PTFE. Design: We report 3 cases of small airways centered granulomatous lesions in workers who had employed at facilities that apply coatings to pans and other utensils. The workers were repeatedly exposed to PTFE particles that were probably generated by the high-pressure air spray and high temperatures (380-420°C) used in the application process. The duration of inhalational PTFE exposure was between 7 and 20 years. We performed light microscopy, electron microscopy, energy-dispersive x-ray analysis (EDS), and chemical component analysis. Results: We found granulomatous lung parenchymal lesions around the terminal and respiratory bronchioles in lung biopsy specimens obtained from the workers. Fourier transform infrared spectrometry analysis and scanning electron microscopy/energydispersive X-ray spectroscopy from the pulmonary tissue specimens identifi ed PTFE by its chemical signature. Conclusions: These cases suggest that recurrent inhalational exposure to PTFE particles causes small airways centered pulmonary granulomatosis.
Next Generation Sequence Profiling of Large Cell Carcinoma/ Solid Adenocarcinoma Defines Distinct Subgroups with Implications for Rational Therapy Selection
MYC Protein Expression Correlates with MYC Amplification in Small
EGFR Mutation Testing in Lung Adenocarcinoma Patients Using Sequenom Assau
Clinical Genotyping of Non-Small Cell Lung Cancers Using Semiconductor Next Generation Sequencing Technology
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Poor (1995-2005, median followup duration: 4 yrs), driver mutations were assessed using Sequenom mass spectrometry genotyping and EGFR exon 19 deletions were identifi ed by a PCR-based assay. Immunostaining was performed for ALK (5A4) using tissue microarrays. Tumors were subtyped according to the IASLC/ATS/ERS classifi cation. Log-rank test was used for overall survival (OS). Results: Correlations between mutations and histologic subtypes or OS are summarized in Table. Lepidic predominant pattern had equal numbers of KRAS mutations and EGFR exon 21 L858R mutations but a signifi cant association was only seen with the latter (p=0.006) and not with exon 19 deletion (p=0.62). More than half of invasive mucinous adenocarcinomas and colloid predominant tumors had KRAS mutations but they did not have any other mutations. Tumors with KRAS mutation showed worse OS than tumors that were negative for driver mutations and ALK (Mut-Neg) (p=0.001) or had EGFR L858R mutation (p=0.051) and exon 19 deletion (p=0.017). Within the solid predominant LADs (n=60), tumors with KRAS mutation showed worse OS than KRAS wild type (p=0.011). Tumors with BRAF mutations showed worse OS than tumors that were Mut-Neg (p=0.008), had EGFR L858R mutation (p=0.009) and exon 19 deletion (p=0.003) although this fi nding was on the basis of a small number of cases (n=8).
Conclusions:
Our data suggest that driver mutations defi ne molecular subtypes of early stage LADs with signifi cantly different prognosis and BRAF and KRAS mutations are poor prognostic factors. A novel fi nding was that within the solid predominant LADs KRAS mutation was a poor prognostic factor for OS.
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Micropapillary Pattern and Invasive Tumor Size Are Prognostic Factors in Invasive Mucinous Adenocarcinoma of the Lung K Kadota, N Rekhtman, AL Moreira, ME Arcila, VW Rusch, PS Adusumilli, WD Travis. Memorial Sloan-Kettering Cancer Center, New York, NY. Background: According to the 2011 IASLC/ATS/ERS lung adenocarcinoma (ADC) classifi cation, invasive ADC with prominent apical intracytoplasmic mucin and small basally oriented nuclei, formerly referred to as mucinous bronchioloalveolar carcinoma, is classifi ed as invasive mucinous ADC (IMA). This classifi cation emphasizes the prognostic signifi cance of histologic subtypes. However, the prognostic impact of these subtypes in IMA is not known. In this study, we determine whether histologic patterns and tumor size can predict prognosis in IMA. Design: All available tumor slides from patients with resected lung IMA (1995 IMA ( -2013 were reviewed (n=93; stage I/II/III: 74/16/3). The percentage of histologic pattern was recorded in 5% increments. Invasive tumor size was measured by subtracting the percentage of lepidic component from the total size. Tumors were classifi ed according to the predominant subtype. Molecular testing (EGFR/KRAS mutation) was performed in 70 cases. Log-rank test was used to analyze recurrence-free probability (RFP). Results: There were 3 mucinous minimally invasive (MIA) (2 pure mucinous and 1 mixed mucinous/nonmucinous) and none of them recurred. The RFP of all IMA (n=90) was 79%, which was between those of intermediate (84% for acinar and 83% for papillary) and high grade (solid for 70%) in non-mucinous tumors (Yoshizawa et al. Mod Pathol 2011) . In IMA, 42 were pure mucinous and 48 mixed mucinous/nonmucinous, but no difference of RFP was observed (p=0.98). In tumors tested for mutations (n=70), no tumors had EGFR mutations but 34 had KRAS mutations, including 17 transversion and 17 transition. Pure mucinous tumors more frequently had KRAS mutations than mixed mucinous/nonmucinous (70% vs. 30%; p=0.002). In tumors stained with the immunohistochemistry, 48 % were positive for TTF-1 (47% in pure and 50% in mixed mucinous/nonmucinous), 95% positive for CK7, 56% positive for CK20, and 6% positive for ALK (clone 5A4). By subtypes, 19 (21%) lepidic, 31 (34%) acinar, and 40 (44%) papillary predominant tumors were identifi ed, but no difference of RFP was observed (p=0.89). The RFP for patients with presence (5%) of micropapillary pattern (n=30; 5-year RFP: 52%) was signifi cantly lower than patients without micropapillary (n=63; 83%; p=0.009). Total tumor size did not correlate with prognosis (p=0.50). However, the RFP for patients with >2 cm invasive size (n=37; 57%) was signifi cantly lower than patients with 2cm invasive size (n=56; 81%; p=0.016). Conclusions: In IMA, invasive tumor size, but not total tumor size, and micropapillary pattern are signifi cant predictors of recurrence. RFP for IMA appears intermediate to poor compared to other ADC subtypes. IMA, especially pure mucinous tumors, frequently had KRAS mutations but no EGFR mutations.
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Is Peripheral Squamous Cell Carcinoma of the Lung a Different Neoplasm Than Central Squamous Cell Carcinoma? A Clinical, Pathologic and Epigenetic Study JA Kalil, J Macagba Slade, L Buckingham, VB Reddy, A Medavaram, R Ghai, P Bitterman, P Gattuso. Rush University Medical Center, Chicago, IL. Background: Squamous cell carcinomas of the lung are categorized by tumor location: central and peripheral. Studies have addressed the clinical, pathologic and molecular characteristics of central squamous cell carcinoma (SCC-C) of the lung, but there is scant literature for peripheral (SCC-P). We undertook a retrospective study to compare the clinical, pathologic and molecular fi ndings of peripheral and central SCC of the lung. Design: Between 1995 and 2011, 135 SCCs of the lung were retrieved from our pathology archives. Sixty-six cases were peripheral and 69 central. Clinical, pathologic and molecular studies (MGMT promoter methylation) were compared between the two groups. Results: Among the 66 patients with SCC-P, 34 were female and 32 male. The ages ranged from 52 to 91 years. Twenty-two patients had a smoking history while in 44 it was unknown. There were 40 T1, 22 T2, 4 T3 and 0 T4 tumors. The visceral pleura was positive in 17 cases, negative in 46 and unknown in 3. Forty-nine tumors were grade II, 16 grade III and 1 tumor was grade I. Of 66 patients, 39 had lymph node sampling and 1 was positive. Among the 69 patients with SCC-C, 28 were female and 41 male. The ages ranged from 45 to 80 years. Forty-two patients had a smoking history, 4 were non-smokers and 23 were unknown. There were 45 T2, 15 T1, 9 T3 and no T4 tumors. The visceral pleura was positive in 20 of 69 cases. Thirty-nine tumors were grade I, 28 grade II and 2 grade III. All 69 patients had lymph node sampling and 22 had positive lymph nodes. MGMT promoter methylation was higher in SCC-C than in SCC-P (average 10.9% vs. 5.3%; p=0.029). Increased methylation levels were seen at all tested cytosines in the MGMT promoter. No differences in promoter methylation were seen in the p16, RASSF1, RASSF5, CDH1, PTEN, SHP1 and LET7 gene Background: Tumor necrosis factor alpha induced protein 8 (TNFAIP8) is a transcription factor NF-kB inducible antiapoptotic and oncogenic molecule. This gene was initially discovered by comparison of expression profi les of primary and metastatic head and neck squamous cell carcinoma (hence earlier referred to as SCC-S2). Positive correlation between TNFAIP8 expression and cancer progression/poor prognosis has been described in a few human solid cancers including pancreatic and esophageal primaries. We were the fi rst to publish the adverse prognostic implication of TNFAIP8 expression in prostatic adenocarcinomas. In this study, we evaluated the signifi cance of this protein in non small cell lung cancer (NSCLC). Design: Formalin-fi xed, paraffi n-embedded sections from 86 NSCLC, including 22 squamous cell carcinomas (SCC), 31 adenocarcinomas (AC), and 33 bronchioalveolar carcinomas (BAC), were immunostained by a manual method using a custom made anti-TNFAIP8 antibody as described earlier (Zhang et al., Int J Cancer,133: 31-42, 2013 Background: Restrictive Allograft Syndrome (RAS) has been recently described as a distinct, aggressive form of chronic lung allograft dysfunction (CLAD) demonstrating restrictive pulmonary function decline and pleuroparenchymal fi broelastosis as a major histopathologic fi nding. We previously reported that RAS is often also associated with features of prior or concurrent acute lung injury/diffuse alveolar damage. Recently, it has been suggested that acute fi brinoid organizing pneumonia (AFOP) is a new form of CLAD, distinct from RAS. We reviewed specimens from RAS patients to classify histologic patterns of acute lung injury and determine whether histologic features of AFOP are present in patients with RAS. Design: We reviewed surgical pathology cases (transbronchial biopsies, open biopsies, re-transplant pneumonectomies, autopsy lungs) from 16 patients with documented RAS, transplanted at our institution between January 1996 and June 2009. Cases with reported features of acute lung injury were assessed for histologic patterns of acute lung injury by two pathologists with subspecialty pulmonary pathology expertise. Results: A total of 42 specimens were available for review. Of these, 29 cases demonstrated acute phase changes characterized by alveolar fi lling by fi brinous exudates (AFOP) and/or classic hyaline membranes (DAD), while the remaining 13 cases showed only organizing phase changes. Of the 29 cases with acute phase changes, 18 cases demonstrated a predominant AFOP (alveolar fi lling) pattern, while 10 demonstrated predominantly classic DAD (hyaline membrane) pattern, with one case demonstrating approximately equal admixture of both patterns. At least focal features of both patterns were identifi able in the majority of cases (21 of 29). Conclusions: Histologic features of AFOP are frequently present in lung pathology specimens from patients with RAS, and are commonly present concurrently with features considered more typical of DAD (e.g. hyaline membranes). These fi ndings suggest AFOP to be part of the histologic spectrum of acute lung injury-related changes associated with RAS, rather than a distinct form of CLAD.
CD200 Is Expressed by Neuroendocrine Carcinoma
Background: CD200 is a membrane bound glycoprotein normally expressed by neurons, endothelial cells, follicular dendritic cells, lymphocytes, macrophages, and granulocytes. CD200 expression may promote tumor formation and metastasis by helping malignant cells evade the immune system. CD200 has been well studied in hematopoietic malignancies including lymphoma, plasma cell myeloma, and acute leukemia. Although less well studied in non-hematopoietic tumors, CD200 expression has been reported in renal cell carcinoma, ovarian carcinoma, neuroblastoma, melanoma, and cutaneous squamous cell and basal cell carcinomas, but not in prostate carcinoma, breast carcinoma, non-small cell lung carcinoma, astrocytoma, or glioblastoma. CD200 expression has not been well-characterized in neuroendocrine neoplasms. Design: After institutional review, archival, formalin-fi xed paraffi n-embedded tissues containing small cell carcinoma and Merkel cell carcinoma were identifi ed. Tissue microarrays containing colon carcinoma, prostate carcinoma, breast carcinoma, pulmonary adenocarcinoma, and pulmonary squamous carcinoma were used as negative controls. CD200 expression was evaluated by immuno-histochemistry (IHC) using a goat anti-human CD200 polyclonal antibody (RD Systems) at a 1:500 dilution. The immunostains were reviewed by a single pathologist, and scored as follows on the tumor cells: negative (0% positive); rare cells positive (<1%); focally positive (1-25%); variably positive (25-75%); and uniformly positive (>75%). Results: CD200 was expressed by 10 of 10 cases (100%) of small cell lung carcinoma, and 7 of 7 cases (100%) of Merkel cell carcinoma. Tissue microarray studies showed no CD200 expression in 12 of 12 colon carcinoma cores, 15 of 15 breast carcinoma cores, 8 of 8 prostate carcinoma cores, and 52 of 52 pulmonary adenocarcinoma cores. 7 of 9 squamous cell carcinoma cores were negative (78%), with 2 of 9 (22%) showing focal positivity. Conclusions: Among the non-hematopoietic neoplasms studied here, CD200 appears to be a highly sensitive marker of small cell lung carcinoma and Merkel cell carcinoma; therefore, CD200 IHC may be helpful in diagnosing these malignancies. It is possible that CD200 expression helps certain tumors evade the immune system, but this area needs to be evaluated in greater detail. Finally, since anti-CD200 antibody therapy is now being developed, CD200 evaluation may have important therapeutic implications for small cell lung carcinoma and Merkel cell carcinoma. Since the majority of lung cancer patients are unresectable, the only diagnostic material often consists of small biopsy specimens obtained by interventional radiologists, pulmonologists and surgeons. Our aim is to investigate whether refl ex testing of small biopsies is feasible and increases compliance with the new guidelines. Design: 209 consecutive cases of lung adenocarcinoma, NSCLC-NOS and large cell carcinoma diagnosed by a subspecialty thoracic pathologist at one institution were reviewed. Following a change in departmental policy to reduce refl ex testing of surgical resections (R) and begin refl ex testing of small biopsies (B), 167 consecutive cases of the same histologies diagnosed by the same pathologist (2012-13) were reviewed. The numbers of total cases, Stage IV/P cases, B and R tested and tested samples that contained suffi cient tumor for EGFR and ALK studies were recorded and compared. Results: From 2011-12, 143/209 (68%) cases, 36/55 (65%) Stage IV/P, 38/95 (40%) B and 105/114 (92%) R were tested. 137/143 (96%) and 63/68 (93%) were adequate for EGFR and ALK, respectively. From 2012-13, 82/167 (49%) cases, 43/48 (90%) Stage IV/P, 73/80 (91%) B and 9/87 (10%) R were tested. 79/82 (96%) and 75/80 (94%) were adequate for EGFR and ALK, respectively. The differences in the numbers of total cases (p-value = 0.0002), Stage IV/P (p-value = 0.0048), B (p-value < 0.0001) and R (p-value < 0.0001) tested between the two groups were statistically signifi cant. Of note, the differences in the numbers of tested samples adequate for EGFR and ALK (both p-values = 1.0000) were not statistically signifi cant. Conclusions: Refl ex testing of small biopsy specimens for EGFR and ALK is practical and facilitates implementation of the new lung cancer biomarker testing guidelines, which are intended to enable oncologists and patients with advanced stage disease to choose optimal therapies. Furthermore, B are usually collected in the outpatient setting, where molecular testing is reimbursed without a waiting period. Background: Diagnosis of atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS) and invasive adenocarcinoma (IA) may be challenging and arbitrary during histologic examination of lung resection specimens. The goal of this pilot study was to determine if there are differences in chromosomal abnormalities between these lesions using fl uorescence in situ hybridization (FISH). Design: Paraffi n-embedded specimens containing AAH, AIS or IA were reviewed by two pathologists and hybridized with FISH probes to 7p12 (EGFR), 5p15, CEP 6, and 8q24 (MYC). A cytotechnologist enumerated signal patterns in up to 100 tumor cells from areas identifi ed as AIS, AAH, or IA and up to 50 cells from 29 normal regions. Polysomy was defi ned as≥3 signals for≥2 probes and a single locus gain was defi ned as≥3 signals for one probe. A specimen was considered FISH abnormal when 3% of cells exhibited polysomy or 10% of cells exhibited single probe gain. Background: Recent application of immunohistochemistry (IHC) using new developed markers for the diagnosis of malignant mesothelioma (MM), along with the short turnaround time (TAT) for results, has made the diagnostic role of electron microscopy (EM) very restricted. However, some cases of malignant mesothelioma demonstrate indefi nite results for IHC stains and need supplemental tools for an accurate diagnosis of MM. Scanning EM (SEM) using paraffi n-embedded biopsy samples is therefore a simple and useful tool for accurately diagnosing cases of MM that are indistinct from metastatic adenocarcinoma (ADC) using IHC. Design: A total of 30 cases involving the pleura or peritoneum were examined: 20 cases of epithelioid MM (EMM) and 10 cases of metastatic ADC. The length and diameter of 20 microvilli in the intercellular spaces of each case was measured from paraffi nembedded tissue on unstained slides after modifi ed SEM procedure. The TAT for SEM procedure using paraffi n-embedded tissue is about 4 hours. The Mann-Whitney U test was used for comparison of the mean length, diameter, and length/diameter ratio. Receiver operating characteristic curve analysis was used to identify the appropriate length/diameter ratio cutoff value and the Chi-square test was used to determine sensitivity and specifi city. Results: EMM tumor cells generally displayed very long and thin apical microvilli. In contrast, ADC tumor cells exhibited short microvilli with slightly broad bases. The mean length and diameter of EMM microvilli were 2.42 (±0.86) μm and 0.34 (±0.32) μm, whereas those for ADC microvilli were 0.85 (±0.39) μm and 0.32 (±0.09) μm, respectively. The mean length/diameter ratio for EMM was 9.50 (±2.58) and that for ADC was 2.71 (±0.85; p < 0.001). The diagnostic length/diameter ratio cutoff value between EMM and ADC was 4.2 (p < 0.001), and sensitivity and specifi city were 96% and 100%, respectively. Conclusions: The SEM procedure using paraffi n-embedded biopsy material for analysis can be applicable to the accurate diagnosis of EMM and can be a supplementary tool for the differential diagnosis between EMM and metastatic ADC. Design: Five hundred and twenty-one cases of primary or metastatic NSCLC diagnosed over 22 months in multiple central New York hospitals were tested for ALK rearrangement using the FDA-approved Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) and evaluated according to the manufacturer's guidelines. All cases were blinded and classifi ed based on the 2011 criteria for lung adenocarcinoma as lepidic, acinar, papillary, micropapillary or solid predominant patterns, mucinous carcinomas and any signet ring/intracellular mucin component. The patients' age, sex and smoking status (if ALK+) were recorded. Results: In line with previously published data, 2.2% of the cases were ALK+ (n=11). ALK+ patients' average age was 51 with a male to female (M:F) ratio of 1.2:1.0. ALK-patients' average age was 67 with the same M:F ratio of 1.2:1.0. The smoking status of 6 ALK+ cases was known: 4 current/former smokers and 2 non-smokers. Table 1 shows the comparative breakdown of the predominant histologic patterns of the ALK+ and ALK-cases.
Loss of Syndecan 1 Expression in Tumor and
Results:
Conclusions: ALK+ carcinomas were found in patients who were, on average, a decade younger than those with ALK-carcinoma. Contrary to previous reports, 2/3 of ALK+ patients with complete histories were smokers (n=6). ALK+ carcinomas had a signifi cantly higher proportion of solid predominant pattern with≥10% signet ring cells than the ALK-ones (36% vs 3%, p < 0.001). Carcinomas with lepidic, papillary, or micropapillary predominant patterns were unlikely to be ALK+. Identifying clinically relevant patterns allows for more accurate identifi cation of patients who may benefi t from ALK rearrangement testing and targeted therapy.
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Epigenetic Regulation of BAX Gene in Neuroendocrine Tumors of the Lung and Its Prognostic Implication I Lamzabi, LE Rosen, L Buckingham, R Jain, W Barbanera, P Bitterman, V Reddy, P Gattuso. Rush University Medical Center, Chicago, IL. Background: BAX is a member of the Bcl-2 gene family that promotes apoptosis by binding to and antagonizing the Bcl-2 protein. It has been well studied in lung tumors with the exception of neuroendocrine lung tumors (NELT); and to our knowledge, there is no published data regarding epigenetic regulation of BAX in this group of neoplasms. The following study was undertaken to investigate the role of epigenetics in the expression of BAX protein.
Design: Formalin fi xed paraffi n embedded tissues from 41 cases of primary NELT including 14 small cell carcinomas (SCLC), 18 typical carcinoids (TC) and 9 atypical carcinoids (AC) were included in the study. Tissue sections were immunostained with BAX antibody to determine the expression. DNA extracted from microdissected tumor tissue was treated with sodium bisulfi te and amplifi ed by PCR using primers to the BAX gene promoter, followed by pyrosequencing. Data was analyzed by Pearson correlation using SPSS statistical software. Results: Loss of BAX expression was positively associated with distant metastases (p<0.001) in NELT and SCLC group (p<0.005). Hypermethylation at cytosines -79 and -75 of the BAX promoter (A of ATG=+1) correlated with distant metastases (p=0.018 and p=0.019 respectively), while hypermethylation at cytosines -57 and -50 correlated with lymph node metastasis (p=0.016 and p=0.009 respectively). In addition, there was more methylation of the -79 (average 8.42 vs 3.8 (p=0.02)) and -75 (average 9.28 vs 3.8 (p=0.01)) sites in SCLC than TC. Lymph node metastasis was associated with cytosine -79 hypermethylation in SCLC (p=0.01) and -57 and -50 hypermethylation in TC (p=0.01 and p=0.009 respectively). However, only weak correlation between BAX expression and BAX promoter methylation was observed. Conclusions: BAX protein appears to be associated with tumor behavior as its loss predict distant metastases in NELT overall, and SCLC specifi cally. This loss of BAX is likely due to an epigenetic phenomenon through a preferential methylation at -79 and -75 sites of the BAX gene promoter. In addition, lymph node metastases in TC were associated with hypermethylation of -57 and -50 sites. The lack of a strong direct correlation between methylation and expression might be due to the interference of post-translational events or additional factors that are yet to be elucidated.
1992
Bcl-2-Associated X Protein (BAX) Expression in Neuroendocrine Lung Tumors I Lamzabi, LE Rosen, L Buckingham, R Jain, W Barbanera, P Gattuso. Rush University Medical Center, Chicago, IL. Background: BAX is a member of the Bcl-2 gene family. Apoptosis regulator BAX promotes apoptosis by binding to and antagonizing the Bcl-2 protein. It has been well studied in lung tumors with the exception of neuroendocrine carcinomas of the lung (NELT), including typical (TC) and atypical carcinoids (AC). In this study, we investigate the expression of BAX protein in small cell lung carcinomas (SCLC), TC and AC of the lung; and its relationship to tumor characteristics and behavior. Design: We searched our surgical pathology records from 1993 to 2011 for cases of typical and atypical carcinoid of the lung with available tissue. Cases of SCLC were randomly selected from an institutional database. Pertinent clinicopathological data was also collected. H  E slides were reviewed and the diagnoses were confi rmed. The cases were then immunostained with BAX antibody, and the immunostain was interpreted by two different pathologists. Data was analyzed by Pearson Correlation on SPSS software. Results: Sixty seven cases of neuroendocrine lung tumors were studied ( 10 AC, 30 TC, and 27 SCLC). Lymph node metastases were seen in 3 AC, 4 TC, and 7 SCLC. Distant metastases were present in 1 AC, 1 TC, and 18 SCLC. When cases were combined, higher expression of BAX was seen in younger patients (p<0.001) and loss of BAX was positively associated with distant metastases (p<0.001). SCLC showed a signifi cant loss of BAX compared to carcinoid tumors, TC and AC (p=0.005 and p=0.003 respectively). Additionally, in the SCLC group, loss of BAX expression was positively associated with distant metastases (p=0.03). Higher expression of BAX correlated with tumor size in only the AC group (p=0.02). There was no difference in BAX expression between the TC and AC groups and no association with distant or lymph node metastases in either TC or AC.
Conclusions: Loss of BAX expression correlates with grade in NELT, as SCLC showed loss of BAX expression when compared to TC and AC. Loss of BAX expression is also positively correlated with distant metastases in SCLC. Therefore, BAX appears to play an important role in the metastatic behavior of SCLC. BAX does not appear to interfere with or regulate the biologic behavior of TC and AC.
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Distribution of Interstitial Lung Diseases in the Elderly: A Clinicopathologic Analysis of 107 Patients at Least 75 Years Old Requiring Surgical Lung Biopsy (2000-2012)
BT Larsen, JH Ryu, LT Vaszar, HD Tazelaar. Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ. Background: Idiopathic pulmonary fi brosis (IPF) is the most common interstitial lung disease (ILD) in elderly patients, and is increasingly diagnosed by imaging alone if defi nite radiologic features of usual interstitial pneumonia (UIP) are seen. Other elderly patients with ILDs without diagnostic imaging fi ndings may undergo a surgical lung biopsy, but the distribution of ILDs in this vulnerable group has not been characterized. Design: All wedge biopsies from patients at least 75 years old with ILD (2000 ILD ( -2012 were identifi ed by searching databases of Mayo Clinic in Minnesota and Arizona. Slides were retrieved and histologic patterns were reviewed. Results: Among 107 patients (mean age 79 yrs, range 75-87; 69 men), 43 presented with acute respiratory failure and 64 presented in the ambulatory setting. Biopsies included at least 2 separate lobes/sites in 82 cases (77%). Of acutely ill patients, only half (21; 49%) showed fi brosis, almost always UIP (20), often (15) with superimposed diffuse alveolar damage (DAD), acute lung injury (ALI), or organizing pneumonia (OP), consistent with acute exacerbation of IPF or other fi brosing ILD. Those without fi brosis showed a variety of fi ndings, including ALI (8), DAD (7), small airway disease (5), granulomas (4), OP (3), eosinophilic pneumonia (3), and/or foamy macrophages (3), suggestive of infections, drug reactions, and other disorders. One showed alveolar hemorrhage. Of ambulatory patients, most (48; 75%) showed UIP-like fi brosis, but more than half of these cases (27) also showed fi ndings suggesting alternate diagnoses such as chronic hypersensitivity pneumonitis or connective tissue disease, most commonly granulomas (15) or lymphoid hyperplasia (7). The other ambulatory cases showed a variety of fi ndings including granulomas (7), OP (3), small airway disease (3), eosinophilic pneumonia (2), unclassifi able fi brosis (2), amyloidosis (1), and ErdheimChester disease (1). Taken together, only 42 (39%) of acutely ill and ambulatory patients showed histologic features compatible with IPF. Conclusions: In elderly patients with ILD who require biopsies for diagnosis, UIP remains the most common histologic pattern, but more than half of biopsies from both acutely ill and ambulatory patients show evidence of alternate diagnoses incompatible with IPF. Even in elderly patients, surgical lung biopsy often provides valuable information to guide clinical management. Background: Most targeted therapy in non-small cell lung cancer has been focused on adenocarcinoma. Recently FGFR1 amplifi cation is found to be present in up to 20% of lung squamous cell carcinoma (SqCC). Several FGFR1 tyrosine kinase inhibitors are currently undergoing clinical trial. Other potential therapeutic targets of lung SqCC are EGFR, KRAS, PIK3CA, BRAF, ERBBs, and DDR2. We evaluated FGFR1 amplifi cation and several other genetic alterations in lung SqCC cases from Korean patients. Design: 291 cases of SqCC were obtained from pathology fi les. FGFR1 copy number was detected using fl uorescence in situ hybridization (FISH). Clinical signifi cance of FGFR1 amplifi cation was measured using Kaplan-Meier survival analysis. For detection of multiple genetic alterations, we used the MLPA SALSA X050-A1 Lung cancer kit (MRC-Holland, Amsterdam). This probe mix contains 27 probes for detecting copy number of PIK3CA, EGFR, MET, FGFR1, PREN, KRAS and ERBB2. It also contains 9 specifi c probes for the mutations of PIK3CA, EGFR, BRAF, KRAS and ERBB2. Results: We defi ned FGFR1 amplifi cation when FGFR1 copy number was greater than 9. Disease-free survival and overall survival was not signifi cantly different between FGFR1 amplifi cation group and non-amplifi cation group. MLPA results showed amplifi cation of FGFR1 (12.7%), PIK3CA (4.8%), EGFR (4.5%), ERBB2 (7.2%). PIK3CA mutations were detected in 2.4% of tumor specimens. Compare to FISH results of FGFR1, the sensitivity of MLPA was 63%. Conclusions: FGFR1 amplifi cation status was statistically not related to survival in most previously published reports. Our data showed no survival difference between FGFR1 amplifi cation and non-amplifi cation group. Using MLPA, 167 cases(57%) were found to have one or more mutations. Most of the mutations have targeting drugs. This method can be useful for fi nding suitable drugs for advanced lung SqCC patients. The most common mechanism for overexpression and activation of anaplastic lymphoma kinase (ALK) in non-small cell lung carcinoma (NSCLC) could be attributed to the formation of a fusion protein. To date, fi ve fusion partners of ALK have been reported, namely, EML4, TFG, KIF5B, KCL1 and PTPN3. Design: Here, we report two novel fusion genes HIP1-ALK and TPR-ALK. Reverse transcriptase polymerase chain reaction and immunohistochemical analysis were used to detect this fusion gene's transcript and protein expression, respectively. We had amplifi ed the full-length cDNA sequence of this novel fusion gene using 5'-rapid amplifi cation of cDNA ends (5'RACE). Results: The causative genomic translocation t(2;7)(p23;q11.23) and t(1;2)(q31.1;p23)) for generating this novel fusion gene was verifi ed using genomic sequencing. In breakapart fl uorescence in situ hybridization analysis for ALK, split of the 5' and 3' probe signals were observed. Reverse transcriptase polymerase chain reaction revealed that the tumor harbored a novel fusion transcript in which exon 21 of HIP1 was fused to exon 20 of ALK in-frame. Conclusions: The novel fusion genes and their proteins HIP1-ALK and TPR-ALK harboring Coiled-coil and kinase domains, which could play a role in carcinogenesis, could become diagnostic and therapeutic target of the NSCLCs and deserve a further study in the future. Background: Vascular endothelial growth factor (VEGF) is one of the most important molecule inducing tumor angiogenesis and its upregulation is related with poor prognosis in various cancers. HIF-1 has been thought to be important activator of VEGF expression. However, studies regarding the relationship between HIF-1 and VEGF in non-small cell lung carcinoma (NSCLC) showed variable results. Recently, several studies indicated transcriptional factor Sp1 is involved in cancer related angiogenesis. Hence, we thought the discrepancy between HIF-1 and VEGF in NSCLC may be explained by Sp1. Design: AA549 human lung adenocarcinoma cell line was transfected with anti-Sp1 siRNA. The mRNA level was compared using quantitative real time PCR and protein expression was shown by immunocytochemistry and western blot. TMA blocks from 66 squamous cell carcinoma (SqCC) and 80 adenocarcinoma were prepared to perform immunohistochemistgry for Sp1, HIF-1 and VEGF. The ordinal regression test was used to evaluate the statistical association between Sp1, HIF-1, and VEGF expression in NSCLC. The Pearson chi-square test was used to evaluate the statistical signifi cance of immunohistochemical results related to clinicopathological parameters. Follow-up information was also obtained for survival analysis. Results: After anti-Sp1 siRNA transfection, mRNA levels of Sp1 and VEGF were decreased simultaneously. On immunocytochemistry, Sp1 and VEGF expressions were reduced signifi cantly, implying Sp1 regulates VEGF expression. Immunohistochemistry showed a signifi cant relationship of HIF-1 and VEGF expression in SqCC (p=0.02) but not in adenocarcinoma (p=0.78). Sp1 was associated with VEGF expression in both of histology (p=0.03 for SqCC and p=0.005 for adenocarcinoma). Sp1 expression was also related with higher T stage (p=0.04) and PCNA index (p=0.04) and showed a near signifi cant correlation with overall survival (p=0.08). Conclusions: we suggest that two different transcription factors are involved in the induction of VEGF expression in SqCC and adenocarcinoma of NSCLC. Sp1 plays an important role in induction of VEGF expression in both histologic types of NSCLC, but this role is more dominant in adenocarcinoma. Sp1 seems to be involved not only in angiogenesis, but also in cell proliferation and growth contributing to tumor progression. However, regarding the role of Sp1 as a prognostic marker, further investigation is needed. 
Analysis of Genetic Alteration in Lung Squamous
Two New ALK Novel Fusion Proteins Identified in Lung Adenocarcinoma
B Lee, M Hong, M Lira, M Mao, K Takeuchi, J Han, J Kim, Y-L Choi. Samsung Medical Center,
The Differential Role of Sp1 and HIF-1 in the VEGF
KRAS Mutation Profiling of Non-Small Cell Lung Cancer by
Background:
The two most commonly mutated genetic "driver" in some non-small cell lung cancers (NSCLCs) encode for the epidermal growth factor receptor (EGFR) and KRAS. Recent studies indicate that patients with mutant KRAS tumors fail to benefi t from adjuvant chemotherapy, and their disease does not respond to EGFR inhibitors. Furthermore, targeting of KRAS mutant NSCLCs has been tried recently. For those, the feasible mutation detection method is required for the accurate test of KRAS status. In this study, we compare two methods in detecting KRAS mutations of NSCLCs, exploring associations with clinicopathologic factors. Design: 136 cases of primary NSCLC was obtained from pathology fi les spanning 2012 to 2013. Clinical information including stage and smoking history was obtained based on clinical records. Direct sequencing and PNA-mediated PCR clamping was performed to all cases. Next generation sequencing (NGS) was used to validate discordant cases. To increase resolution of low level somatic mutant molecules within a high background of wild-type molecules, PNA-mediated PCR clamping was used for mutant enrichment before NGS. Results: 21(15.7%) of the 136 cases were found to have missense mutation by direct sequencing. When using PNA-mediated PCR clamping method two more cases (case 92 and case 133) were found to have missense mutation. Case 92 is a sample from mucinous carcinoma. The size of tumor was 1cm and the tumor volume contained in the sample was about 20%. Case 133 is from adenocarcinoma resected after neoadjuvant chemotherapy, showing only about 5% of the tumor volume in specimen. The percentage of KRAS mutation detected in case 92 and case 133 is 2% and 4%, respectively in NGS. KRAS mutation allele was defi nitely increased in NGS after using PNA-clamping up to 90% and 89% in both cases. Clinically, KRAS mutation tend to be present in tumors of smoker (p=0.012) and stage IV tumors had more frequent KRAS mutation (p=0.032). Conclusions: Although statistical signifi cance was not reached, more cases were found to have KRAS mutation when PNA-mediated PCR clamping method was used. The result of two discordant case was confi rmed by NGS method. Direct sequencing can accurately detect mutations when percentage of tumor cells in the analytical sample is enough. However, we cannot always get enough tumor volume. In that situation, PNAmediated PCR clamping method can quickly provide result with suffi cient sensitivity.
RNA In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Napsin A Expression in Lung Adenocarcinomas
F Lin, J Shi, H Liu. Geisinger Medical Center, Danville, PA. Background: Expression of napsin A and thyroid transcription factor 1 (TTF1) by immunohistochemistry (IHC) was reported in approximately 75% of primary lung adenocarcinomas (ADCs), and this pair of immunomarkers plays a crucial role in differentiating lung ADC from lung squamous cell carcinoma (SCC) and identifying a primary lung ADC when working on a tumor of unknown origin. RNA in situ hybridization (RNAscope) is a newly described, highly sensitive technique using a bright-fi eld in situ hybridization-based assay to visualize targeted cellular RNA in formalin-fi xed paraffi n-embedded tissue sections. Because approximately 25% of primary lung ADCs are negative for both napsin A and TTF1 by IHC, there is a need to explore a more sensitive technique to detect these biomarkers. In this study we investigated the diagnostic sensitivity of RNAscope in the detection of napsin A expression in primary lung ADCs and compared it to IHC techniques. Design: IHC for napsin A (clone EP205) was performed on tissue microarray (TMA) sections containing 76 lung ADCs and 80 lung SCCs. RNAscope was also performed on these TMA sections to detect mRNA of napsin A according to the protocol from Advanced Cell Diagnostics, Inc. The procedure included de-paraffi nization, pretreatment, target probe hybridization, signal amplification, and colorimetric reaction. The targeted probes prepared by the same vendor covered napsin A sequence from nucleotides 233 to 1172. The scoring system for RNAscope was based on these criteria: 0 (1 dot/tumor cell), 1+ (2-3 dots/tumor cell), 2+ (4-10 dots/cell), 3+ (>10 dots/cell), and 4+ (>10 dots/cell and more than 10 cells). The IHC staining intensity and distribution were recorded. Results: The result of RNAscope for napsin A showed that 89.5% lung ADCs had detectable mRNA, with 4+ in 74% cases, whereas only 76% were positive by IHC. The RNAscope signal was easily detectable even at low magnifi cation. An example of lung ADC with 4+ positivity by RNAscope is shown in the fi gures below. Napsin A expression was not seen in SCCs using either IHC or RNAscope.
Conclusions:
These data suggest that RNA in situ hybridization technique is superior to IHC in detecting napsin A expression in primary lung adenocarcinomas.
Histologic Features and Ki-67 Proliferative Index of Excised
Neuroendocrine Tumors of the Lung SZ Liu, BA Alexiev, KC Tuttle, AP Burke. University of Maryland, Baltimore, MD. Background: The histopathologic distinction between carcinoids, atypical carcinoids and large cell neuroendocrine tumors is based partly on mitotic index. Mitotic counts can be diffi cult to assess, especially on small biopsies or when the rate is low. To date, there are no established criteria for interpreting quantitative Ki-67 index for pulmonary neuroendocrine tumors. Design: We identifi ed 52 lung neuroendocrine tumors and classifi ed them into typical carcinoid (n=35), atypical carcinoid (n=7), and high-grade neuroendocrine carcinomas (8 large cell/LCNEC, 1 recurrent small cell carcinoma). Two LCNEC had areas of adenocarcinoma, one in situ. Ki-67 proliferative index was calculated using validated nuclear algorithm on Aperio digital image analysis on representative tumor. Results: There was a strong correlation between mitotic count and Ki-67 index (R 2 =0.81, p<0.001). The mean mitotic count and Ki-67 for typical, atypical, large cell neuroendocrine tumors were 0.05/2.52%, 4.14/16.84%, and 48.44/71.59% respectively.
There were signifi cant differences in mitotic index and Ki-67 between typical, atypical, and large cell/small cell neuroendocrine tumors (p <0.001). For typical and atypical neuroendocrine tumors, there was no correlation between mitotic count or Ki-67 and tumor size, tumor stage, or nodal stage. Two typical carcinoid tumor had nodal metastasis while one atypical carcinoid had a nodal metastasis. Both typical and atypical carcinoid tumors did not reoccur after resection. Seven typical carcinoids and two atypical carcinoids had spindled morphology. LCNECs showed areas of insular (6/8), trabecular (4/8), and focally glandular (2/8) and spindled growth (1/8); in some areas the tumor was indistinct from small cell carcinoma. Two LCNEC had areas of adenocarcinoma, one in situ. Tumor necrosis was universally present in LCNEC tumors but only present in 2/7 atypical carcinoid tumors. Conclusions: Ki-67 index separates typical from atypical carcinoids at a level of 10% quantitative labeling. Large cell neuroendocrine carcinomas all have a Ki-67 index of > 50%, similar to small cell carcinomas, and, at resection, often have areas resembling small cell carcinoma.
Correlation of Twist Expression in Different Histologic Subtypes of Primary Adenocarcinoma in Lung
A Malek, C O'Hara, H Kathuria. Boston Medical Center, Boston, MA. Background: Tumor recurrence and metastasis have signifi cant impact on the mortality of lung cancer. Metastasis is particularly associated with early demise. Transcription factors that mediate the epithelial-mesenchymal transition(EMT) play a major role in facilitating metastasis by a variety of mechanisms. Twist a basic helix-loop-helix transcription factor is well known to be involved in promoting metastasis. The role of Twist in lung cancer has not been studied well due to the lack of a reproducible classifi cation. This has been addressed by the International Association for the Study of Lung Cancer which has published guidelines for a multidisciplinary classifi cation of lung adenocarcinomas that highlights the heterogeneity of lung adenocarcinomas and establishes a uniform classifi cation. In the new system, lung adenocarcinomas are classifi ed as lepidic, acinar, papillary, micropapillary and solid types; each with prognostic signifi cance. This study attempts to correlate Twist positivity with the various subtypes and account for the prognostic variability encountered in the treatment and outcome of patients. Design: A total of 30 lung adenocarcinomas were subtyped according to the IASLC proposal and stained with Twist monoclonal antibody. Twist staining less than 10% was considered negative, greater than 10% considered positive.
Correlation was measured between Twist results and the histologic subtypes. Results: Kruskal-Wallis analysis on Twist positive cases showed a signifi cant difference among fi ve histologic subtypes (P<0.0001). The most common subtype was Acinar followed by Solid To date, no study has systematically quantitated these changes with attention to the variable and distinguishing characteristics of these entities. Design: Three age-and sex-matched cohorts were evaluated: normal (n=5), LHD (n=10), and PVOD (n=10). In each case, 10 vessels, including: 6 small pulmonary vessels (<200 μm in diameter), 2 pulmonary arteries (200-600 μm in diameter), and 2 pulmonary veins (200-600 μm in diameter), were assessed. Percent intimal thickness (%IT), % medial thickness (%MT), and adventitial thickness (AT) were measured. Hemodynamic data was retrospectively collected from echocardiograms obtained prior to tissue sampling. Measures were compared via regression models utilizing generalized estimating equations (multiple vessels per patient).
Results:
The mean %IT in small vessels in LHD was less than in PVOD (28.0% vs 38.1%, p=0.01) and both were greater than in normal (16.8%, p<0.001). The mean %IT in pulmonary arteries was also lower in the LHD cohort (7.7%) than in the PVOD cohort (17.1%) (p=0.008). There was a trend to lower %IT in pulmonary veins in LHD (28.9%) than in PVOD (41.3%) (p=0.08). The signifi cance of all of these features was however eliminated when results were normalized to right ventricular systolic pressures (RVSP). %MT in pulmonary arteries was lower in LHD (15.7%) than in PVOD (27.6%) or normal (13.2%) (p<0.0001), though the difference in %MT of the pulmonary veins was not as signifi cant. Mean AT of pulmonary veins was also less in LHD than in PVOD (26.1 μm vs 36.4 μm, p=0.03).
Conclusions:
This study demonstrates distinct morphometric differences in LHD and PVOD patients, particularly in small vessels (<200 μm in diameter). These differences disappeared when the after results were normalized to RVSP, suggesting that the hemodynamic status is a primary determinant for pulmonary vascular pathology in LHD and PVOD.
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Localized Malignant Epithelioid Mesothelioma SE Mann, CA Moran, N Kalhor. MD Anderson Cancer Center, Houston, TX. Background: Malignant Mesothelioma is an uncommon tumor that usually presents with diffuse pleural involvement and caries a dismal prognosis. Rarely, this tumor can present as a localized intraparenchymal mass or focal pleural lesion. The patient prognosis is variable, but is often better than the diffuse counterpart with some patients showing no recurrence of disease many years after surgery. Design: A search of our pathology fi les yielded 1002 cases of malignant mesothelioma from 11/2005 to 10/2013. Only 4 cases of localized mesothelioma were identifi ed, corresponding to < 1% of all mesotheliomas. The patient ages range from 42 to 78 years. Three cases are intrapulmonary masses with attachment to the visceral pleura. The fourth case showed pleural thickening found within a wedge resection for an adjacent neuroendocrine tumor. Clinically, the patients were asymptomatic related to their mesothelioma and in three cases, the intraparenchymal masses were identifi ed radiologically for unrelated issues. In the fourth case, the focal pleural lesion adjacent to a neuroendocrine tumor was not identifed prior to surgery. History of asbestos exposure was not stated in any of the patient histories. Results: Histologically the findings of three cases are epithelioid malignant mesothelioma characterized by nests of polyhedral cells with round nuclei and moderate eosinophilic cytoplasm and the fourth case is a sarcomatoid malignant mesothelioma with the classical features of pleomorphic spindle cells growing in short fascicles. All four cases were positive by immunohistochemical stain for anti-calretinin and for cytokeratin. The three epithelioid mesothelioma cases were positive for cytokeratin 5/6 which was negative in the sarcomatoid malignant mesothelioma. One patient had a recurrence of tumor involving lung and diaphragm four years after the original workup and surgery. Two cases are very recent and a reasonable follow-up interval has not elapsed. One patient remains alive after 8 years with no recurrence of mesothelioma. Conclusions: Localized malignant mesothelioma is exceedingly rare compared to the diffuse type. These localized tumors share the same histologic and immunohistochemical profi les as the diffuse type, but differ radiologically and in clinical presentation. Although the course of disease is diffi cult to predict, some patients enjoy an extended disease-free interval compared to patients with diffuse malignant mesothelioma. These tumors can be diagnostic pitfall for the practicing pathologist. Awareness of this entity with a place in the differential diagnosis of solitary lung lesions is essential to avoid errors in diagnosis. (n=33), biphasic (n=18) and sarcomatoid (n=11) MPM's. One epithelioid case was excluded due to tissue loss. HE and immunohistochemical stains for laminin alpha-1 (part of Ln-111 and Ln-121) and laminin gamma-2 (unique to Ln-332) were performed. Stains were scored for intensity (0-3+) of cytoplasm. Results: Laminin alpha-1 was intracellular in 93% of MPM cases. Staining intensity was lowest in epithelioid cases and highest in sarcomatoid. In contrast, laminin gamma-2 was expressed in 51% of MPM cases and showed no preferential pattern between the subtypes. Detailed results are shown in Figures 1 and 2 (E=Epithelioid, B-E=Epithelioid biphasic, B-S=Sarcomatoid biphasic, S=Sarcomatoid).
Conclusions:
Both laminin alpha-1 and laminin gamma-2 are expressed in the cytoplasm of malignant mesothelial cells. However, whereas gamma-2 demonstrates no predilection according to morphologic subtype, alpha-1 steadily increases in intensity from pure epithelioid cases to the epithelioid component of biphasic cases and then even further sarcomatoid component of biphasic and pure sarcomatoid. Sarcomatoid morphology is known to portend the poorest prognosis in MPM patients and laminin alpha-1 staining may be useful prognostically.
2004
Combined T-cells are highly diverse, with multiple subsets that may potentially be exploited for immunomodulatory therapy, including CD8+ cytotoxic T-cells, regulatory T-cells (Treg, CD4+Foxp3+) and those expressing programmed death-1 (PD-1). The current study was aimed at understanding the contribution of these various populations to MPM infi ltrates. Design: Tissue microarrays (TMA) were constructed using epithelioid (n=33), biphasic (n=18) and sarcomatoid (n=11) MPM cases. Two epithelioid cases were excluded from analysis due to tissue loss. Routine HE staining, double immunohistochemical staining for Foxp3 with either CD4 or PD-1 and single staining for CD3 and CD8 were performed. CD3 and CD8 were scored as low (no cluster consisting of more than 10 cells) or high (>10 cells in a given cluster). CD4+Foxp3+ and CD4+PD-1+ cells were scored according to the maximum number of double-stained cells per high power fi eld (hpf, 400X). Results: All MPM infi ltrates demonstrated CD3+ and CD8+ T-cells. CD3+ infi ltrates were low in 55% of cases and high in 45% of cases, while CD8+ T-cells were somewhat fewer, with 82% of cases scored as low and 18% scored as high. CD4+Foxp3+ and PD-1+ cells were present in 98% and 90% of cases, respectively, and 88% of cases demonstrated both populations. PD-1+ cells tended to outnumber CD4+Foxp3+ cells, with an overall average of up to 22.0 and 16.7 cells per hpf, respectively. PD-1+Foxp3+ cells were present in only 55% of cases, and when present, they were few (up to 0.9 cells per hpf on average).
Conclusions: MPM cases demonstrate infi ltrates containing multiple T-cell subsets within any given case, including Treg and PD-1+ lymphocytes in additional to conventional CD8+ T-cells. Immunomodulatory therapies targeting each of these populations are currently in development and have demonstrated success in murine models. It is tempting to speculate that the mixed nature of this infi ltrate may afford the opportunity for synergistic effects from targeting multiple populations simultaneously.
MET Status before Tyrosine Kinase Inhibitor (TKI)-Start Predicts Treatment Responses in EGFR-Mutant Lung Adenocarcinoma
A-SK Meyer, R Marienfeld, S Rudiger, P Muller, P Moller, C Schumann, JK Lennerz. University Ulm, Ulm, Germany; Hospital Guenzburg, Guenzburg, Germany. Background: The type of EGFR mutation in non-small cell lung cancer (NSCLC) is predictive for tyrosine-kinase inhibitor (TKI) responses. TKI-resistance limits responses and among several oncogenic drivers, MET causes resistance in at least 30% of patients. MET-positive NSCLC is clinically more aggressive and the predictive infl uence of MET remains unclear in TKI-treated EGFR-mutant NSCLC. Here, we tested the METstatus as a biomarker for TKI-response in EGFR-mutant lung adenocarcinoma (ADC). Design: The inclusion criteria for this retrospective study were: EGFR-mutation within exon 18-21, histologically confi rmed ADC (Stage III/IV), TKI-treatment for at least 1 mo., clinical follow-up and suffi cient tissue for MET assessment by immunohistochemistry. Primary outcome measure was overall response to TKI (OR) at end of observation. Secondary outcome measures were best radiological response (BR, by CT, RECIST 1.1), progression free (PFS) and overall survival (OS There was no association of MET with PFS or OS; however, patients with PD had the shortest PFS and OS (P PFS :<0.0001; P OS :<0.0001; log-rank).
Conclusions:
Patients with MET-tumors show better responses than patients with MET+ tumors. While, the cohort size is a limitation, the stringent selection criteria are necessary to test the value of MET as biomarker in this specifi c setting. Given the statistically signifi cant effect of MET status to TKI-response in our cohort, ongoing trials inhibiting both MET and EGFR, and the simplicity of the MET assessment, our fi ndings should warrant validation in independent larger cohorts.
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EGFR Mutational Analysis in Non-Small Cell Lung Carcinomas by Allele Specific PCR on Fine Needle Aspiration Derived Cell Pellets EC Minca, J Brainard, S MacNamara, C Farver, PC Ma, AV Arrossi, NA Penell, RR Tubbs. Cleveland Clinic, Cleveland, OH. Background: Epidermal growth factor receptor (EGFR) gene mutation status in advanced non-small cell lung carcinomas (NSCLC) directs targeted therapy with EGFRspecifi c inhibitors, including erlotinib and gefi tinib. EGFR mutations are commonly tested by Sanger sequencing or allele specifi c polymerase chain reaction (ASPCR) on formalin-fi xed paraffi n-embedded (FFPE) samples. Cytology specimens obtained by fi ne needle aspiration (FNA) represent an alternative valuable resource in cases when FFPE tissue is insuffi cient, unavailable or improper, which at our institution comprise approximately half of cases tested. Here we present the validation of ASPCR on FNA derived cells pellets and FFPE samples for detecting EGFR mutations in a NSCLC case series at our institution. Design: The validation study included 100 samples from patients with advanced NSCLC clinically referred for EGFR mutation testing: 39 FNA cell pellets, 17 cytoblocks and 44 FFPE biopsies. ASPCR was performed using the EGFR RGQ PCR Kit (Qiagen) that detects 29 somatic EGFR mutations against a background of wild-type genomic DNA. DNA extracted and quantifi ed from all samples was also sent for external testing at CLIA and CAP accredited facilities (Genzyme, Clarient, and Dahl-Chase). Results: The ASPCR assay performed at our institution returned EGFR mutations in 35/100 samples and wild type EGFR in 65/100 samples. The results were concordant with those of external testing in 98/100 cases (98%). The 2 discordants, involving 1 cytoblock and 1 FNA pellet, were interpreted as apparent false-positives, but may refl ect a greater sensitivity of the in-house ASPCR assay. The assay had acceptable intra-assay, inter-assay and inter-lot reproducibility (%CV <10%), and an analytical sensitivity level of 10% mutant allele. The clinical sensitivity, specifi city, positive and negative predictive values were 100%, 94.3%, 97% and 100%, respectively for the whole study, and 100%, 87.5%, 96.9% and 100%, respectively, for the FNA pellets alone. Conclusions: ASPCR can reliably detect EGFR gene mutations in FNA cell pellets as in FFPE samples from patients with NSCLC. The high sensitivity of the assay in FNA specimens warrants the routine use of FNA cell pellets for clinical EGFR mutation testing on in NSCLC cases with unavailable or improper FFPE material. EC Minca, C Lanigan, JP Reynolds, Z Wang, PC Ma, F Almeida, NA Pennell, RR Tubbs. Cleveland Clinic, Cleveland, OH. Background: Oncogenic ALK gene rearrangements in non-small cell lung carcinomas (NSCLC) provide the basis for targeted therapy with crizotinib and other specifi c ALK inhibitors. Treatment eligibility is conventionally determined by the FDA-approved companion diagnostic fl uorescence in-situ hybridization (FISH) assay on formalinfi xed paraffi n-embedded (FFPE) tissue. On limited samples such as fi ne needle aspiration (FNA)-derived cytoblocks, FFPE-FISH for ALK is often uninformative due to insuffi cient tumor cells, absence of enumerable signals, or autofl uorescence. FISH performed on liquid based ThinPrep slides may represent a robust alternative to conventional FFPE-FISH. Here we assessed the feasibility of ALK testing by ThinPrep-FISH in an extended NSCLC case series. Design: ALK-status was tested on 230 FNA samples (ThinPrep slides and cytoblocks) from 217 patients with advanced NSCLC, including 179 consecutive samples collected from 174 patients between 12/2012 and 08/2013 at Cleveland Clinic. ThinPrep-FISH was performed using a standard ALK break-apart probe set (Abbott Molecular Vysis) and scored in areas with abundant tumor cells etched with a diamond-tip pen on the reverse side of the slide. Due to the high failure rate of FFPE-FISH on cytoblocks (>30% in our preliminary experience), we used ultrasensitive ALK immunohistochemistry (IHC) on corresponding cytoblocks [D5F3 antibody (Cell Signaling) with OptiView signal amplifi cation (Ventana)] as the reference data set (J Mol Diagn 15:341-6). Results: Cytoblocks were unavailable in 19/230 (8.2%) cases and lacked suffi cient tumor cells in 57/230 (24.7%) cases, despite the presence of abundant tumor cells on the ThinPrep slide. ALK ThinPrep-FISH was informative in 228/230 (99%) cases, displaying robust signals, uncompromised by nuclear truncation inherent in FFPE-FISH. 9/178 (5%) informative cases in the consecutive series and 18/228 (7.8%) informative cases overall were ALK-rearranged. Of 154 informative matched ThinPrep-FISH and cytoblock-IHC samples, 152 were concordant (10, 6.5% ALK-status positive; 142, 92.2% ALK-status negative), and 2 (1.3%) were ThinPrep-FISH positive but IHC negative (sensitivity 100%, specifi city 98.6%, overall agreement 98.7%). Conclusions: ALK [/italic]gene rearrangements are reliably detected by FISH using ThinPrep slides derived from minimally-invasive FNA cytopathology samples. ThinPrep-FISH can be confi dently used for clinical ALK testing in NSCLC cases.
2007
ALK Testing in Non-Small Cell Lung Carcinoma by FISH on Fine Needle Aspirate Derived ThinPrep Slides
2008
Restrictive 
Results:
Biopsies from RAS and PPFE showed subpleural, paraseptal and broncocentric fi broelatosis, with mild to moderate numbers of fi broblastic foci and infl ammation. No microscopic honeycombing was noted. When comparing to UIP cases, there was a striking decrease of the interstitial capillary network (Fig.1B CD34 in PPFE/RAS and D. CD34 in UIP) as well as intimal fi brosis in medium size vessels ( Figure 1C ). Medial wall infl ammation involving medium size vessels (arteries and veins) was seen in all patients diagnosed as RAS ( Figure 1A) .
Conclusions: RAS and PPFE histopathology consisted of intra-alveolar fi brosis and elastosis with distinctive fi bro-infl ammatory vascular morphology and interstitial capillary loss. Although interstitial fi broelastosis have already been described in both diseases, we identify novel vascular changes, which may allow further understanding of their pathogenesis.
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EGFR L858R Antibody Cross-Reaction in HER2 Positive Breast and Gastric Carcinomas V Montse, R Natalia, R Ruth, T Isabel, P Carme, A Nuria, M Begonya, G-P Beatriz, P Xavier. Histopat Laboratoris, Barcelona, Spain; BIOPAT. Biopatolodia Molecular, Grup Assistencia, Barcelona, Spain; Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain. Background: The use of epidermal growth factor receptor (EGFR) mutation-specifi c antibodies is likely to get soon incorporated into clinical practice due to its proven correlation with the presence of EGFR mutation in lung adenocarcinoma, especially in cases with limited tumor material, or in situations where molecular genetic analysis is not readily available. The use of these antibodies has also been suggested as an additional tool for distinguishing primary versus metastatic carcinomas in the lung. Incidental fi ndings in our routine practice and a recently published paper reporting false positive breast carcinomas for EGFR L858R, made us think about the possible existence of a cross-reaction between HER2 and the EGFR L858R-specifi c antibody. Aims of this study were to further analyze the existence of this cross-reaction and its frequency in the two common sources of metastatic tumors to lung, breast and gastric cancer; in which, in addition, HER2 expression is widely studied in relation to targeted therapies. Design: The series consists of 55 primary tumors, 22 breast and 5 gastric carcinomas HER2 positive for overexpression and amplifi cation, and 20 breast and 8 gastric carcinomas negative for both. EGFR mutations were studied by immunohistochemistry with two specifi c monoclonal antibodies (EGFR [E746_750del] clone 6B6 and EGFR L858R clone 43B2) in all cases, and confi rmed using real-time PCR when positive. Results: In our study 86% (19/22) of HER2 positive breast carcinomas and 100% (5/5) of HER2 positive gastric carcinomas showed EGFR L858R positive expression, and equivocal in 14% (3/22) of HER2 positive breast carcinomas, while no expression was found in none of the HER2 negative carcinomas. All cases were negative using the EGFR exon19 [E746_750del] antibody. Real-time PCR did not confi rm the presence of the EGFR L858R mutation on neither of the 24 positives nor of the 3 equivocal cases by IHC. Conclusions: EGFR L858R antibody gives false positive results in most of breast and gastric carcinomas with HER2 overexpression/amplifi cation. The existence of this cross-reaction makes necessary verify any EGFR L858R positivity by molecular methods and discard the presence of HER2 overexpression/amplifi cation in order to establish its clinical signifi cance. Background: Concerning clinical assessment of lung cancer, molecular-based approach is getting more important. When we think based on morphological heterogeneity, response to molecular-target therapy might not be very simple. The goal of this study is to evaluate signifi cance of the morphological heterogeneity and the gene alteration of lung cancer, using FFPE-based miRNA expression profi le. Design: 52 lung cancer, including 43 adenocarcinoma (Ad), 6 squamous cell carcinoma (Sq), and 3 pleomorphic carcinoma (Pleo), were recruited. Average age was 62-yo, 28 male and 24 female, 20 ALK-altered, 10 EGFR-mutated. Using the FFPE material of surgically resected specimen, the comprehensive miRNA expression profi le was examined by SurePrint G3 human MicroRNA microarray, Rel.16.0 (Agilent). The representative area of morphological subtype (h_sub) based on a new IASLC/ATS/ ERS classifi cation was micro-dissected. Total 122 samples (including 19 lepidic (lep), 23 papillary (pap), 25 acinar (aci), 10 micropapillary (mipp), 22 solid (sol), 1 mucinous (muc) h_sub Ad, 13 Sq, 5 Pleo, 4 normal lung) were submitted. Hierarchical clustering and differential expressed probes by moderated t-test were calculated using Genespring GX (ver 12.6) (Agilent). Results: Unsupervised hierarchical clustering revealed three groups; cluster-1 EGFR Ad, cluster-2 Ad with any genotype, cluster-3 Sq and Pleo. ALK-altered Pleo was included in cluster-3. Supervised clustering revealed the difference among the conditions of histology, of genotype and of h_sub. The number of differential expressed miRNA probe between each category (p value<=0.05, FC>=2.0) was as follows; 34 between Ad and Sq (Ad/Sq), 38 lep/aci, 26 lep/sol, 5 lep/pap, 3 lep/mipp, and none in all the remainder h_sub combinations. The miRNA profi le would be considered as the biological indicator of difference between each condition. 96 miRNAs (excluding 202 duplicated entities), such as hsa-miR-144*, hsa-miR-182, hsa-miR-139-5p, were differentiatel expressed among the h_sub conditions. Among the genotype condition, 77 miRNAs (excluding 9 duplicated entities), such as hsa-miR-921, hsa-miR-494, hsa-miR-3648 were differentially expressed. Conclusions: Our study suggested biological significance of histomorphologic difference of lung cancer in addition to the genetic abnormalities. These differential expressed miRNAs could be diagnostic indicators and/or new therapeutic targets. Background: Up to 20% of patients with lung cancer will present with multifocal lung nodules. Staging, treatment and prognosis is predicated on classifying these lesions as either synchronous primaries or metastatic disease. When excised, the histologic comparison can aid in this determination. However, in most cases, only biopsies or radiologic determination is used to make this assessment. Our study aimed at making this distinction using large genomic rearrangements identifi ed by Next Generation Sequencing. We hypothesized that metastatic tumors should have at least one shared somatic breakpoint resulting from these rearrangements while synchronous primaries should not share any. Design: The study group included 11 patients with synchronous lung tumors of similar histologic type, pathology used to determine the likelihood of tumors being synchronous primaries versus metastasis. Control groups included: 4 patients with paired lung primary and distant metastasis, 3 patients with synchronous lung cancers of different histologic types and 4 patients with multiple blocks of tissue of a single lung cancer. Laser capture microdissected tumor and adjacent normal tissue were whole genome amplifi ed. Next generation DNA sequencing using the Mate Pair protocol was used to analyze large genomic rearrangements and selected fi ndings were validated by PCR. Results: All 1ary lung tumors and distant metastasis shared between 4-85 breakpoints (46-89% of detected breakpoints) and blocks of a same tumor shared between 4-276 (50-100%). In contrast, the synchronous tumors of different histologic type did not share a single breakpoint (out of 39-162). For the study group, 4 cases were predicted to be synchronous primaries, 5 to be metastatic and 2 were considered indeterminate. For all cases of synchronous primaries, no shared breakpoint was identifi ed (of 6-69 breakpoints) and 4 of the 5 metastasis showed between 4-85 shared breakpoints (46-89%). For the 2 indeterminate cases, the genomic data suggested synchronous primaries with no shared genomic breakpoint identifi ed. All selected breakpoints validated through PCR. Furthermore, there was not a single shared genomic breakpoint between tumors from different patients in both groups. Conclusions: Large genomic rearrangement sequencing is a robust method to distinguish synchronous lung primaries from metastasis. Breakpoints are unique to patients and to patient tumors such that sharing a common breakpoint would indicate clonality. Performing this study in a larger group of patients and determine clinical feasibility will be important. Background: The differentiation of malignant and benign mesothelial proliferations is crucial in determining patient care and prognosis. But, this distinction can be extremely diffi cult, particularly in small biopsies. Recently, insulin-like growth factor II mRNAbinding protein 3 (IMP3) and glucose transporter 1 (GLUT-1) have been reported as specifi c and sensitive markers in the distinction of malignant mesothelioma from benign mesothelial proliferations. The purpose of this study is to evaluate the utility of IMP3, GLUT-1, and epithelial membrane antigen (EMA) immunohistochemistry for distinguishing malignant mesothelioma from benign mesothelial proliferations. Design: We performed IHC for IMP3, GLUT-1 and EMA using tissue microarrays of 47 malignant pleural mesotheliomas, 41 peritoneal mesotheliomas and 35 adenomatoid tumors for benign mesothelial proliferation. The malignant pleural mesotheliomas cases (pleuropneumonectomy, n=20; excision, n=27) and malignant peritoneal mesothelioma (excision, n=41) are selected from archives of Korea Nationwide Malignant Mesothelioma Surveillance tissue bank between 2002 and 2012. Cytoplasmic staining in≥10% of target cells was considered positive for IMP3 and EMA and membranous tatining in≥10% of target cells was considered positive for GLUT-1. Results: Sensitivity and specifi city of IMP3, GLUT-1, and EMA expression in malignant mesothelioma and benign mesothelial proliferation are summarized in Table 1.   Table 1 . IMP3, GLUT-1, and EMA expression in malignant mesothelioma and benign mesothelial proliferation IMP3 (n=87) IMP3 and EMA staining showed diffuse and strong pattern. The GLUT-1 showed diffuse and strong staining for red blood cells and endothelial cells but patchy staining for tumor cells. Conclusions: Although IMP3, GLUT-1, and EMA expression was statistically signifi cant in mesotheliomas compared with benign mesothelial proliferations, it is unsuitable as individual marker because of low sensitivity. Use of IMP3 and EMA together could improve sensitivity and help in distinguishing malignant from benign mesothelial proliferations. Combined panel of immunohistochemical stains could be a useful approach. 
Significance of Morphological Heterogeneity of Lung
Distinction between Synchronous Lung Primary
GLUT-1 (n=87) EMA (n=88) IMP3+GLUT-1 (n=87) IMP3+EMA (n=88) GLUT-1+EMA (n=88) Malignant 32 (37%) 18 (21%) 36 (41%) 39 (45%) 58 (66%) 47 (53%) Benign (n=35) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Liposarcomas of the
Design:
We have studied sixteen cases of liposarcomas (LPS) presenting in the posterior mediastinum. Immunohistochemical stains and fl uorescence in-situ hybridization (FISH) were done in selected patients. Results: Ten patients were men and six were women, aged 29 to 87 years (mean: 57). The tumors presented clinically as large lobulated masses that ranged from 8 to 30 cm in greatest diameter (median: 15). The most common symptoms were cough, dysphagia, chest pain and abdominal pain. Six patients were asymptomatic and the tumors were discovered incidentally on chest X-rays. Histologically, 10/16 cases were atypical lipomatous tumor/well differentiated liposarcoma; 3/16 pleomorphic liposarcoma, 2/16 de-differentiated liposarcoma and 1/16 myxoid liposarcoma. Immunohistochemistry for MDM-2, S-100 and MIB-1 was performed in only three cases; one case of atypical lipomatous tumor showed positivity for S-100 and MDM-2. FISH was performed in two cases of atypical lipomatous tumors and showed high levels of amplifi cation of MDM2 at 12q13-15 in two cases, whereas the CHOP gene translocation was negative.
Complete surgical excision was performed in ten cases; negative surgical margins were obtained in only four cases. Clinical follow up data ranging from 3 to 192 months (median 28 months) was available in 12 patients. Two patients died of tumor, one after 4 months and the second one after an open-and-close surgery (myxoid liposarcoma and pleomorphic liposarcoma, respectively). Four patients (4/10) were alive and well with no evidence of disease at last follow up (median: 11.8 months); fi ve patients (5/16) were alive with disease at last follow up (median: 47.8 months); and one patient (1/16) died of unrelated causes. Conclusions: All major histologic subtypes of liposarcoma were represented in the posterior mediastinum. In general, the biologic behavior of liposarcoma in the posterior mediastinum seems to correlate well with the histologic subtype and mirrors that of their counterparts at other soft tissue sites. p<0.01, 73.1% vs. 39.1%, p=0.02, and 46.2% vs. 17.4%, p=0.03) . Other fi ndings did not show signifi cant differences. 16 of UIP/LD-CTD and 6 of IPF-neg fulfi lled the histological criteria of LD-CTD. Any histologic fi ndings reached signifi cant difference between RA/SjS suggestive cases and PM/DM/SSc suggestive cases. During follow up, 1 case of UIP/LD-CTD was diagnosed as defi nite CTD. Conclusions: 3 out of Fischer's 4 criteria reasonably associated with clinical LD-CTD cases, although their specifi city is not robust enough for criteria. Some of current IPF cases may fulfi ll the histological criteria of LD-CTD, however, clinical importance of such cases is not certain. Further large studies to evaluate clinical difference between IPF-neg and UIP/LD-CTD and reproducibility and importance of histological criteria are needed. V Parimi, R Raj, Y-H Chen, K Raparia. Northwestern University, Chicago, IL. Background: Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2) and mediates epigenetic silencing of target genes through trimethylation of lysine 27 on histone H3 (H3K27me3). EZH2 confers a proliferative advantage in tumor cells and is overexpressed in breast and prostate cancers and epigenetically silences tumor suppressor genes. Clinicopathological implications of EZH2 expression in lung adenocarcinoma has not been studied. Design: EZH2, pEZH2, H3K27me3, PTEN and Ki-67 were evaluated in 162 patient samples of lung adenocarcinoma by immunohistochemistry (IHC) on formalin fi xed paraffi n embedded tissue microarrays. Immunostains were graded for nuclear intensity and percentages of positively stained tumor cells and divided into three groups: negative, low and strong expression. Pathologic and clinical characteristics were correlated and analyzed using appropriate parametric and nonparametric statistical methods.
EZH2 Overexpression as a Novel Prognostic Marker in Lung Adenocarcinoma
Results:
Of the 162 patients, 54 patients showed strong expression and 73 patients showed low expression of EZH2. Patients with expression of EZH2 comprised of 87 females and 40 males with mean age of 66 years. Clinical and pathological characteristics of patients with strong expression of EZH2 when compared to those with low/negative expression are summarized below. Background: Zinc fi nger transcription factor GATA-3 is essential for early T-lineage progenitor development and controls T-helper type 2 (TH2) differentiation. Overexpression of GATA-3 has been reported in breast and urothelial carcinomas and is used in diagnostic surgical pathology to differentiate metastatic breast or urothelial carcinomas from prostatic or lung origin. In this study, we investigated the expression of GATA-3 in malignant mesotheliomas (MM) using tissue microarrays (TMAs). Design: Tissue microarray was created using 0.6 mm tissue cores in triplicates from 94 diagnosed mesothelioma cases. GATA-3 antibody (Clone L50-823; Biocare, CA) was used and immunostaining was performed after heat-induced epitope retrieval. Nuclear immunoreactivity for GATA-3 antibody was scored (staining intensity and percentage positive cells) and at least 2+ staining intensity in >25% tumor cell nuclei was considered as positive staining. Appropriate tissue controls were used, and lymphocytes present were used as internal positive controls. Results: In our study, 61 cases revealed presence of evaluable tissue cores; majority were pleural mesotheliomas (54/61; 88%). 20 of these 61 cases (33%) revealed positive nuclear staining for GATA-3. Fifteen of these were pleural mesotheliomas, 2 peritoneal mesotheliomas, 2 with both involved and 1 case where site was unknown. Nuclear GATA-3 immunoreactivity was noted in epithelioid (13/20 cases; 65%, (Figure 1 ) and in sarcomatoid mesotheliomas (Figure 2 ).
Conclusions:
To date, GATA-3 positivity has not been reported in a series of mesotheliomas. Our study demonstrates GATA-3 expression in 25-30% of MM, including both epithelioid and sarcomatoid types. We also demonstrate that GATA-3 can be expressed in peritoneal mesotheliomas. Currently GATA-3 is used in the workup of metastasis of unknown primary, and based on our fi ndings, we suggest that mesotheliomas should also be included in the list of GATA-3 positive tumors along with urothelial and breast carcinomas.
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Morphology Outperforms Immunohistochemistry on Subtyping of NSCLC in Biopsies S Petkiewicz, H Sekhon, C Lai, P Wheatley-Price, M Gomes. University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada. Background: Histological subtyping on biopsies of NSCLC is necessary for therapeutic purposes. Up to 50% of biopsies may have no diagnostic morphological features, and the 2011 IASLC classifi cation suggests use of immunohistochemistry (IHC) for such cases. An IHC panel of TTF-1 and p63 is recommended for differentiating squamous (SCC) and adenocarcinoma (AC), however, there is evidence that p40 is more specifi c than p63 for diagnosing SCC. Design: Paired biopsies and resections with NSCLC diagnoses were selected (37 cases). Using strict IASLC morphological criteria, two lung pathologists independently reviewed the slides and rendered diagnoses. Consensus diagnosis was made for any cases with disagreement. Cases that could not be diagnosed on morphology alone were designated as "NSCLC." IHC and special stains were performed on select slides from both biopsies and resections (TTF-1, mucicarmine, p63, p40). Staining was coded using IASLC criteria and the results compared with the morphology-only diagnoses. Results: Every resection showed either squamous or glandular morphological differentiation (AC, n=25; SCC, n=12). Using resection diagnoses as the gold standard, specifi c diagnoses were rendered on 92% of biopsies using morphology alone, and those diagnoses, after consensus, concurred with resection diagnoses in 100% of cases, yielding sensitivities (sens) of 92% and specifi cities (spec) of 100% for both SCC and AC. For IHC staining panels, TTF-1+/p63-had sens=60% and spec=100% while TTF-1+/p40-had sens=76% and spec=100% for AC. For SCC, p63+/TTF-1-had sens=82% and spec=96% while p40+/TTF-1-had sens=90% and spec=96%. Mucicarmine had sens=32% and spec=82% for diagnosis of AC on biopsy. In the three cases in which morphology was not suffi cient for a fi nal diagnosis, IHC directed a diagnosis consistent with the resection in 2 cases and the third case, an AC, had insuffi cient tissue for TTF-1 staining but mucicarmine was positive and p63 and p40 were negative. Conclusions: Morphology outperformed IHC alone in diagnosing lung cancer biopsies. Replacing careful morphological examination with IHC or use of IHC in cases which show diagnostic morphology may be misleading, time consuming and exhaust tissue.
IHC is a valuable tool in cases with no morphological differentiation. A simple panel of TTF-1 and one squamous marker is suffi cient, p40 being more specifi c than p63. For AC, mucicarmine has poor sensitivity but may be helpful in porly differentiated cases. Background: Nodular amyloid deposition (NAD, "amyloidoma") is a rare disease defi ned by mass-forming deposition of amyloid. Few studies of NAD exist to date, its pathogenesis is incompletely understood and molecular studies are rarely undertaken in clinical practice. We aim here to characterize NAD clinical and pathologic features, to retrospectively classify the underlying disorder, and to evaluate the utility of molecular studies in patients with NAD. Design: Eighteen patients were identifi ed with amorphous nodular deposits in our fi les; 2 were reclassifi ed as light chain deposition disease and 4 were eliminated due to insuffi cient material/information. Clinical-radiological information, histo-morphologic fi ndings of the index lesion and bone marrow, and laboratory studies including serum or urine protein electrophoresis (SPEP/UPEP) and immunofi xation (SIFE/UIFE), molecular studies (PCR B-cell clonality using IgH FR1-3, IgK primes) performed on bone marrow, blood and/or tissue specimens were reviewed. All clinical, pathologic and molecular information was integrated at review. Results: Among the twelve patients, six were men and six women. The average age at diagnosis was 62.6 years (range 35 to 87 years). The location of nodular amyloid was lung (6 cases), brain (2 cases), soft tissue (3 cases) and pharynx (1 case). The main lesion size ranged from 0.9 to 7 cm (2.5 cm average). Three patients (25%) had concurrent autoimmune connective tissue disease. All NADs showed sparse lymphoplasmacytic infi ltrate and a diagnosis of lymphoma or multiple myeloma was suggested in only three patients (25%) at the time of original report. Five cases were originally assigned to surgical pathology and seven cases to hematopathology. Eight of the twelve tumors tested demonstrated evidence of B-cell clonality either by kappa/lambda IHC (6 cases) and/or PCR (6 cases) in the amyloid deposition samples. These tests were concordant in only two cases. Bone marrow clonality was present in most cases tested (5 of 6 cases). Four cases showed no evidence of clonality. SPEP/SIFE showed a monoclonal protein in only three of twelve cases. Seven clonal cases were classifi ed as low grade B cell lymphoma with plasma cell differentiation, while one patient had a plasma cell neoplasm. No patient had evidence of systemic amyloidosis at fi rst diagnosis. Conclusions: The underlying disease in most NAD is a clonal B-cell expansion or neoplasm with plasma cell differentiation which is diffi cult to diagnose due to paucicellular lymphoplasmacytic infi ltrate. Clonality studies should be performed and systemic work-up suggested when reporting NAD. Background: Mutation of the tumor suppressor gene phosphatase and tensin homologue (PTEN) is seen in various malignancies. PTEN encodes a dual specifi city protein phosphatase that negatively regulates phosphatidylinositol 3-kinase/AKT signaling, a pathway with an established role in promoting cell cycle progression and survival. We evaluated the expression of PTEN in lung adenocarcinoma and correlated with clinical, pathological and molecular features. Design: Tissue micro-arrays containing 162 lung adenocarcinoma samples in triplicates were immunostained with anti-PTEN and anti-MIB antibodies. PTEN expression in the tumor was graded for intensity (negative: 0; mild: 1; moderate: 2 and strong: 3) and percentage of tumor cells positively stained. Less than 10% tumor cells with mild nuclear/cytoplasmic staining were considered having loss of PTEN. All patients with lung adenocarcinoma were followed from 0 to 136 months (median 30 months). Pathologic and clinical characteristics were correlated and analyzed using appropriate parametric and nonparametric statistical methods. Results: Seventy six patients (47%) had loss of PTEN expression. These patients included 47 (62%) females and 29 (38%) males with mean age of 66 years (range 43 to 91 years). Patients with loss of PTEN had larger tumors (2.9 cm versus 2.1cm, p=0.004) (Figure 1 ) and were less likely to have lepidic predominant adenocarcinoma (8% versus 23%, p=0.07).
Prognostic Significance of ROS1 Protein Expression in Non Small
Patients with loss of PTEN expression were more likely to have a higher stage disease (p=0.006). Higher Ki-67 proliferative index showed a modest correlation with loss of PTEN expression (p=0.12). PTEN loss was seen in 24 patients with KRAS mutation and 10 patients with EGFR mutation. Conclusions: Loss of PTEN protein expression occurs frequently in lung adenocarcinoma and portends a poor prognosis in terms of its association with increased tumor size, higher proliferative index and higher stage lung cancer.
Hybrid Sarcoidosis and UIP -Sarcoidosis Variant or Distinct
Histopathologic Entity? N Rao, JF Tomashefski. Medical College of Wisconsin, Milwaukee, WI; Metrohealth Medical Center/Case Western Reserve University, Cleveland, OH. Background: Pulmonary sarcoidosis may progress to advanced interstitial fi brosis. Some end stage sarcoidosis features may be distinctive; however, other fi brosing conditions with granulomas, notably chronic hypersensitivity pneumonitis (HP), may pose diagnostic challenges. We present five cases of granulomatous lung disease consistent with sarcoidosis, spatially separated from a UIP pattern in adjacent parenchyma. This dual lung injury pattern appears distinctive from fi brotic phase sarcoidosis, and chronic HP, and warrants separate recognition and further study. Design: 5 cases of a granulomatous process consistent with sarcoidosis, with background advanced interstitial fi brosis form the study. Clinical information was available in 4/5 cases -2 males and 2 females, 50 -55 years old (mean age -52). All presented with dry cough and dyspnea. Chest CT showed interstitial fi brosis with peripheral/axial involvement (1/4), peripheral honeycombing and traction bronchiectasis (2/4), and lung base fi brosis (1/4). 4 patients had surgical lung biopsies; the 5th underwent lung biopsy followed by lung transplantation. Follow up was available in 2/5 patients. One is alive and well 5 years after diagnosis, following lung transplantation; the other has died of disease 5 years after diagnosis. Results: Well circumscribed granulomas with characteristic lymphatic distribution, patchwork fi brosis, architectural remodeling and fi broblastic foci were present in all cases. One case showed end stage lung with advanced fi brosis. All cases had characteristic separation of granulomatous foci from adjacent UIP pattern fi brosis (Fig 1) .
Mediastinal lymph nodes (2 cases), showed diffuse involvement by granulomatous infl ammation with associated sclerosis.
Conclusions:
We have characterized the pathologic features of 5 cases of granulomatous disease consistent with pulmonary sarcoidosis with synchronous UIP. The histologic features and distribution of granulomas, their spatial separation from UIP, and granulomas in mediastinal lymph nodes, should allow separation from chronic HP. While these fi ndings may represent a sarcoidosis variant, coexistence of sarcoidosis and UIP cannot be excluded.
IgG4 Positive Plasma Cell Infiltration in Lung Adenocarcinoma Is
Common and May Be a Marker of Anti-Tumorigenic Immune Response K Raparia, V Parimi, R Raj. Northwestern University, Chicago, IL. Background: IgG4 related disease can be associated with lung adenocarcinoma. Signifi cance of IgG4 plasma cell infi ltrate in lung cancer is not well understood. Although few case reports and small case series describe IgG4 positive plasma cell infi ltration in tumor stroma of lung cancer patients, the degree and frequency of IgG4 plasma cell infi ltrate in patients with lung cancer has not been systematically studied. Design: Tissue microarrays containing 162 lung adenocarcinoma samples in triplicates were immunostained with anti-IgG4 and anti-IgG antibodies. Pathologic and clinical characteristics were analyzed and correlated. Results: 43% patients (n=70) had IgG4 positive plasma cells/HPF ranging from 1 to 65 (mean 5.3) (Figure 1 ) and IgG4/IgG ratio of 1.25 to 100% (mean 29%) (Figure 2 ). 1 6 (10%) tumors had more than 20 IgG4 positive plasma cells/HPF and more than 25% IgG4/IgG cells (designated IgG4 enriched tumors). Mean IgG4/IgG ratio in the IgG4 enriched tumors was 58% (25-100%). Patient characteristics of IgG4 enriched cases: 10 females, 6 males, median age 66 years and mean tumor size 2.8cm (range 0.8 to 8cm). All the patients with IgG4 enriched plasma cells with Stage 1 disease were alive at the end of median follow up of 36 months. Conclusions: IgG4 positive plasma cell infi ltration is relatively common in lung adenocarcinoma, with a minority of patients meeting diagnostic criteria for IgG4 related disease suggesting that the IgG4 positivity may represent an immune response to yet unidentifi ed tumor antigens. There was a trend towards better survival in patients with IgG4 enriched tumors, suggesting that this immune response has anti-tumorigenic properties and could confer a survival advantage. This needs to be further confi rmed in larger prospective studies. ). An intracystic component <25% was found in 6 and pronounced nuclear atypia and perineural invasion in 1 each. All cases with available gross description (n=10) had a central/endo-or peribronchial location. Tumor-associated lymphoid population was present in 19 (of 21) cases. Tissue blocks were available in 12 cases. The distribution of p63 and p40 staining in tumor cells was concordant in all cases except one (p63 score-4, p40 score-3). Scores for p63 and p40 were 1 (n=5), 2 (n=2), 3 (n=1) and 4 (n=3). TTF-1 and napsin were neg in tumor cells in all cases. MAML2 rearrangement was identifi ed in all cases tested including low (n=3), intermediate (n=8), and high grade (n=1) PMEC. Clinical history was available in 11 pts: M:F = 7:4 (median age 48 yrs, range, 32-75). F/u was available in 9 pts (median f/u 5.3 years, range, 1.1-13.8). One pt died of unknown causes, one developed metastatic MEC. Background: Early diagnosis is still the most important prognostic factor in NSCLC. Despite that, up to 30% of these patients recur. The aim of this study was to identify oncogenic alterations that can help to understand the molecular biology of this heterogeneous group of tumors. Design: We retrospectively analyzed a cohort of 52 patients with NSCLC diagnosed at stage I from 1995 to 2011. We recorded the histopathological characteristics of these tumors listed in each pathology report (histologic type, size, vascular/pleural invasion) and obtained follow up of 46 patients. We studied total and phosphorilated forms of 4E-BP1, eIF4E, mTOR, MAPK, S6 and YB1 by immunohistochemestry in paraffi n-embedded whole sections. Levels of expression were semiquantitatively evaluated paying attention to intensity and percentage of staining in both nucleus and cytoplasm (hscore). For the statistical analyses we performed Kruskal-Wallis and Kaplan-Meier tests. Results: The mean age was 63.12 years, male/female ratio was 42/10 and diagnoses included 18 squamous cell carcinomas (SQ) and 36 adenocarcinomas (ADC). We observed statistically signifi cant higher expression of 4E-BP1 and p4E-BP1 in SQ compared to ADC (p<0.001 and 0,002). pmTor and pS6 in contrast, were higher in ADC (p<0.001 and =0.04). We did not observe any signifi cant relation between expression and size or pleura/vascular invasion. 9 out of 46 (19.56%) recurred (4 SQ and 5 ADC, 1 Tis, 7 T1 and 1 T2). Kaplan-Meier test showed statististically signifi cant longer period of disease-free survival (DFS) for patients with lower expression of pmapk and no relation to other tumor characteristics. Conclusions: We have found differences in cell signaling factors expression between early stage SQ and ADC and association between some of these factors and DFS. Larger series studies will be carried out to fi nd out the prognostic or predictive value of these cell signaling factors. Background: Lung adenocarcinoma, especially adenocarcinoma in situ (AIS), often occurs in individuals who have never smoked, although smoking is the main cause of lung cancer. Design: To characterize AIS and, in particular, determine how AIS might be related to smoking, we collected a large number of AIS cases and examined clinicopathological features, EGFR and KRAS mutation status, and activation status of receptor tyrosine kinase (RTK) downstream signal pathways, including pAkt, pERK and pStat3, using immunohistochemistry.
Results:
We identifi ed 111 AIS among 1,549 adenocarcinomas resected surgically during 1995-2010. There was a higher ratio of female non-smokers, but not male nonsmokers, in AIS compared with invasive adenocarcinomas (p< 0.001). Smoking was not associated with other clinicopathological factors including expression of TTF-1, a cell lineage marker. EGFR mutations were identifi ed in 41 of 71 (58%) non-smokers and 19 of 31 (61%) smokers, and KRAS mutations were in one of 71 (1.4%) nonsmokers and two of 34 (5.9%) smokers. For pAkt and pERK, around 40-50% of AIS were positive, and for pStat3, over 80% were positive, with no signifi cant differences in either for activation rates between non-smokers and smokers. Mucinous AIS rarely harbored KRAS mutations. Taken together, compared with invasive counterparts, AIS occurs predominantly in females and non-smokers. However, characteristics of AIS arising in non-smokers and smokers were similar in terms of cell lineage, driver mutations and RTK pathway activation. Conclusions: Our results suggest that AIS is not simply a precursor of invasive adenocarcinoma and that smoking may not be a cause of AIS. Rather, smoking may play a role inprogression of AIS to invasive adenocarcinoma with AIS features. Background: The utility of routine histologic examination of lung specimens from patients with clinically primary spontaneous pneumothorax (SPTX) has been questioned in the surgical literature. However, in our experience, histologic examination of SPTX specimens yields fi ndings that impact clinical management. We present the fi rst detailed retrospective histopathologic assessment and cost analysis addressing whether routine histologic examination of clinically primary SPTX specimens is justifi ed. Design: Clinical and radiographic records of all patients undergoing surgical resection for SPTX at our institution from 2002-2012 and corresponding histologic slides were reviewed. Each specimen was assessed for histologic features typically associated with SPTX, as well as unexpected fi ndings. Results: Seventy-two patients considered clinically to have primary SPTX were identifi ed, with 78 cases available for review. All cases demonstrated one or more fi ndings typically associated with SPTX. Clinically signifi cant unexpected histologic fi ndings were identifi ed in 7.7% of cases: 1 case of lung carcinoma, 1 case showing endometriotic stroma-lined cysts and adenomyosis on subsequent hysterectomy interpreted as pulmonary stromal endometriosis, 1 case with histologic fi ndings compatible with Birt-Hogg-Dube syndrome (BHD) subsequently confi rmed by genetic testing, and 3 cases consistent with "bong lung" with marijuana use confi rmed on followup. With the exception of a cyst seen grossly in the case of stromal endometriosis, no distinctive gross fi ndings were noted in cases with signifi cant unexpected histologic fi ndings. Conclusions: Gross examination alone is inadequate for detecting unexpected clinically signifi cant fi ndings in lung specimens from patients with clinically primary SPTX. By contrast, routine histologic examination does identify unexpected fi ndings that alter patient management and/or have important implications for relatives. In our series, these included a previously unrecognized case of BHD, which confers a substantial risk of renal carcinoma. According to our analysis, the cost of histologically examining all primary SPTX specimens received in a 10-year period is less than the average reported cost of treating one patient for advanced stage renal carcinoma. This is the fi rst study to demonstrate that clinically primary SPTX specimens should be routinely examined histologically and is a cost-effective means of detecting unexpected fi ndings with signifi cant clinical impact. Background: Although the presence of tumor infi ltrating lymphocytes (TILs) has been associated with survival benefi t in non-small cell lung cancer (NSCLC), the effect is signifi cant but modest. In most instances the immune system generates only a partially effective anti-tumor response. Activation of the PD-1/PD-L1 axis induces tumor immune evasion and blockade of this pathway using immunostimulatory antibodies shows prominent anti-tumor responses. We determined the association between TILs, PD-L1 protein, PD-L1 mRNA and outcome in two retrospective NSCLC cohorts. Design: The level of TILs, PD-L1 protein and in situ mRNA were measured in 544 stage I-IV NSCLC samples represented in two TMAs (Yale cohort [YC] n=204; and Greek cohort [GC] n=340). The level of TILs was determined by pathologist evaluation of HE stained preparations using a 4-tier scale (0-3+). PD-L1 protein and mRNA were measured by quantitative fl uorescence using the antibody clone 5H1 and the RNAscope paired-primer assay. UbC mRNA was used as positive control and DapB as negative control. Association of the variables with clinico-pathological characteristics and overall survival were determined. Results: Elevated TILs (categories 23+) were found in 34% of cases from the YC and 38% of the GC. PD-L1 protein expression was detected in 36 and 25% of patients of the YC and GC, respectively. PD-L1 mRNA expression was found in 51% of cases from the YC and 53% of the GC. In both collections, PD-L1 protein and mRNA showed a positive non-linear relationship (R 2 =0.182 in the YC and R 2 =0.337 in the GC). In univariate analysis, the presence of increased TILs was positively associated with PD-L1 protein and mRNA expression. Elevated TILs, PD-L1 protein or mRNA expression were independently associated with longer overall survival (log rank P=0.009 in the
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Expression Patterns of FABP5 Are Associated with Grade of Pulmonary Neuroendocrine Tumors SM Smith, CA Powell, MW Nasser, J Fukuoka, J Jen, TJ Franks, WD Travis, RK Ganju, K Shilo . The Ohio State University, Columbus, OH; Nagasaki University, Nagasaki, Japan; Mayo Clinic, Rochester, MN; Joint Pathology Center, Silver Springs, MD; Memorial Sloan-Kettering Cancer Center, New York, NY. Background: The transport of fatty acids within the intracellular compartments is dependent on a family of 14-15 kDa proteins referred to as fatty acid binding proteins (FABPs). Epidermal FABP, also known as FABP5, is expressed most abundantly in epidermal cells and also in adipocytes, macrophages and dendritic cells. FABP5 has been found to be over-expressed bladder, breast and prostate carcinomas. Whether FABP5 has a role in tumorigenesis of lung neuroendocrine tumors (LNET) is unknown. This study seeks to delineate FABP5 expression patterns in LNET and potential correlation with clinicopathologic fi ndings. Design: Tissue microarray based samples from 184 patients with LNET were evaluated for FABP5 expression with a polyclonal goat anti-human antibody (1:100, RD Systems, Minneapolis, MN). FABP5 expression was assessed in comparison to normal lung parenchyma as cytoplasmic (negative, low and high) as well as dendritic (nuclear/ cytoplasmic) staining (<50% cells, low), (50% cells, high) and negative. The expression patterns were correlated with clinicopathologic variables (SYSTAT, Chicago, IL). Consequently, EGFR has become a target for anti-cancer drug therapy. The most common mutations associated with sensitivity to EGFR TKIs include exon 19 deletions and the L858R point mutation. These mutations are currently detected by Sanger sequencing in our Molecular Lab. Small biopsies are frequently used for lung cancer diagnosis resulting often in specimens with low tumor content. Microdissection is performed for most specimens to reach 30% tumor cells to meet the detection sensitivity of sequence based assays. In this study we examine the utilization of new anti-EGFR L858R (SP125) and anti-EGFR E746-A750 del (SP111) rabbit primary monoclonal antibodies in FFPE tissues. Design: Thirty one (31) cases of lung adenocarcinoma with adequate FFPE tissue previously tested for EGFR mutations in our molecular lab were selected. Ten (10) cases were wild type, nine (9) cases were positive for the EGFR L858R mutation and twelve (12) were positive for the EGFR exon 19 deletions (9 had del E746-A750 and 3 contained other deletions). All cases were stained with both anti-EGFR L858R and anti EGFR E746-A750 del antibodies (Ventana Medical Systems, Inc, Tucson AZ), using the Ventana BenchMark Ultra immunohistochemical (IHC) stainer platform. Moderateto-strong staining by IHC was considered positive result; absent or equivocal staining was considered negative. The results were obtained by consensus of four pathologists. Results: All cases (n=9: 100%) that were positive for the EGFR L858R mutation by sequencing were also positive by IHC (anti-EGFR L858R antibody); none of these showed positivity for the anti EGFR E746-A750 del antibody. The nine (9) of twelve (12) cases that were positive for the EGFR exon 19 deletion E746-A750 by sequencing were also positive by IHC (anti EGFR E746-A750 del antibody); the (3) specimens with other exon 19 deletions were negative for this antibody. None of these 12 showed positivity for the anti-EGFR L858R antibody. All ten cases that were wild type by sequencing were negative by IHC for both antibodies. Conclusions: Immunohistochemistry on FFPE tissues with monoclonal antibodies specifi c for L858R and the most common form of exon 19 deletion may be of clinical effi cacy in the initial evaluation of lung adenocarcinomas and serve as a guide to further molecular analysis. Background: Malignant pleural mesothelioma (MPM) with its epithelioid and sarcomatoid pattern allows for studying intrinsic epithelial-mesenchymal (EMT) transition. Cells undergoing EMT may display stem cell (SC) traits. We hypothesized that the neural crest stem cell markers Sox10 (transcription factor Sry-box 10) and nestin (intermediate fi lament protein) may be related to the "M-end", thus to sarcomatoid MPM and to the EMT marker periostin (extracellular matrix). Sox10 regulates the nestin neural enhancer in melanoma. Design: Tumor tissue of 192 consecutive MPM patients was analysed by IHC on tissue microarrays. 111 patients underwent trimodal therapy including neo-adjuvant chemotherapy (CTX), either cisplatin/gemcitabine or cisplatin/pemetrexed, following extrapleural-pleuropneumonectomy (EPP) and optional adjuvant radiotherapy. Pre-CTX biopsies were available for 88/111 EPP patients. 81 patients had either pleurectomy/ decortication (P/D) or no surgery performed. Immunoreactivity was H-scored (intensity multiplied by frequency) on 2 cores (biopsy) or 4 cores (surgical specimen), respectively, for a total of 926 cores. Results: The histologic MPM pattern was epithelioid in 112 (58%), biphasic in 69 (36%) and sarcomatoid in 11 (6%). High protein expression of nuclear Sox10 as well as cytosolic nestin and periostin in tumor cells increased towards the sarcomatoid pattern, the 3 proteins also being positively correlated among each other. In particular, nestin distinguished between epithelioid and biphasic but not between biphasic and sarcomatoid in both pre-and post-CTX MPM. Sox10 distinguished between biphasic and sarcomatoid in pre-CTX but between epithelioid and biphasic in post-CTX. Cis/ Gem but not Cis/Pem CTX increased Sox10 and periostin. Sox10 also increased in 5 MPM diagnosed as epithelioid on biopsy but biphasic on surgical specimen. Sarcomatoid pattern and high nestin correlated with poor prognosis in all patients. In the EPP subset, high nestin (median overall survival 21.9 versus 25.5 months), high pT, high pN and lung infi ltration were adversely prognostic next to histology (all p-values <0.05). Conclusions: Next to the loss of diagnostic markers calretinin and D2-40, the sarcomatoid "M" end of MPM is characterized by an increase of stem cell traits. Protein expression of Sox10 and nestin is further modulated by chemotherapy. Background: Tumors have developed multiple mechanisms to shut down the immune pathway for surveillance against cancer. The programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway has emerged as an important tumor evasion mechanism. Two recent clinical trials highlighted the therapeutic potential of an agent that targets PD-1/PD-L1 in patients with advanced non-small cell lung cancer (NSCLC). However, the challenge has been the identifi cation of predictive biomarkers that could be used to identify potential candidates for such treatment. In the current study, we use immunohistochemistry (IHC) to evaluate PD-L1 expression in stage IV lung cancer. Design: We retrospectively reviewed 24 patients with stage IV lung squamous cell carcinoma or adenocarcinoma. Sections of formalin-fi xed tumor specimens were subjected to IHC to evaluate the patterns of PD-L1 expression. Results: The tumor specimens included 14 adenocarninomas, six squamous cell carcinoma and four NSCLC. The expression of PD-L1 was demonstrated in the cell membrane, cytoplasm, or both (clone 5H1).
Interestingly, 67% of the stage IV lung squamous cell carcinoma expressed high level of PD-L1. Of the stage IV NSCLC, 25% expressed PD-L1, (Table 1) whereas none of the stage IV adenocarcinoma expressed PD-L1. Design: -A total of 90 cases of NSCLC with complete follow-up were retrieved from the Surgical Pathology fi les: 60 adenocarcinomas (AC) and 30 squamous cell carcinomas (SCC).
-Using tissue microarrays specimens, we investigated the expression of CD24, CD44, D2-40, ALDH-1 and SOX-2.
-The log-rank (Mantel-Cox) test and Kaplan-Meier estimation were used to estimate the probability of overall survival (OS) and disease-free survival (DFS). Results: -Patients age ranged from 47 to 85 years; 70 men and 20 women.
-SOX-2, CD44, ALDH1 and D2-40 overexpression was predominantly seen in SCC whereas expression of CD24 was most common in AC (p < 0.05).
-Overall, there was a statistically signifi cant relationship between low expression of CD24 and better OS (cut-off value of 50; p=0.02). By histologic subtype, similar results were observed in AC (CD24 overexpression related with lower DFS and OS; p=0.01 and 0.06).
-Globally, CD44 expression was more commonly associated with improved OS (p=0.08). In a subgroup analysis, a signifi cant association was evident in AC (increased OS and DFS, p=0.045 and 0.12; cut-off values of 5) -SOX-2 overexpression in AC was related to an improvement in both OS and DFS (p=0.18 and 0.07; cut off value 50) Other markers showed no relation with survival. Conclusions: Our fi ndings suggest that overexpression of CD24 is a signifi cant predictor of poor outcomes in AC. Although it did not reach statistical signifi cance, the relationship observed in AC between SOX-2 and CD44 overexpression and increased survival is interesting, as it suggests their potential use as prognostic markers. There are confl icting results in the literature regarding the expression of CSC in lung tumors. Our results provide new insights in the pathways involved that could be relevant for the selection of patients' treatments.
Peilobular Margination by Elastosis: A Robust Histologic Marker of Usual Interstitial Pneumonia
T Ushigusa, T Tanaka, K Tsuruno, N Tawada, K Tabata, Y Kashima, K Kataoka, Y Kondoh, H Taniguchi, J Fukuoka . Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Toyama University Hospital, Toyama, Japan; Tosei General Hospital, Seto, Aichi, Japan. Background: Accurate distinction of histological usual interstitial pneumonia (UIP) from other patterns, especially non-specifi c interstitial pneumonia (NSIP), is often challenging for pathologists. We routinely use Elastica van Gieson (EVG) staining to highlight elastic fi bers for lung cases and have noticed that perilobular accumulation of elastic fi ber is a frequent fi nding in UIP. We investigated the usefulness of this elastic fi ber accumulation in UIP and NSIP cases. Design: We retrospectively selected surgical lung biopsy from 87 consecutive chronic interstitial pneumonia cases under the diagnosis of either UIP or NSIP. All cases had biopsied samples from segment 5 and 9. The amount of elastic fi ber accumulation in the margin of lobules (Perilobular margination by elastosis: PLME) was semiquantitatively graded with EVG staining: 0, none; 1, mild; 2, moderate; 3, severe by 2 pathology trainees, and among in several lobules inside the biopsy, 5 highest scores of PLME were obtained for each biopsy (Fig.1 ). Average and highest PLME score for each biopsy were calculated by the obtained scores. All data were acknowledged as reasonable by senior pathologists.
Results:
The kappa agreement of the 2 observers was 0.63 (S5) and 0.60 (S9). PLME score was positively correlated with UIP histology in both S5 and S9 for both average and highest scores (all p values < 0.0001). Among them, the receiver operating characteristic (ROC) curve provided that S9 average PLME score, cutoff of 1.6, and S9 highest PLME score, cutoff score of 2.0, as the best (Fig.2) . When highest S9 PLME score was applied, the specifi city was 100%.
Conclusions: PLME identifi ed by EVG staining was a distinctive, easy, and reproducible marker for UIP. More than moderate level of PLME in lung base can be strong negative indicator of NSIP. Background: ALK gene rearrangement defi nes a distinct molecular subtype of non-small-cell lung cancer (NSCLC) that responds to ALK tyrosine-kinase inhibitor crizotinib. Defi ning distinctive clinical and morphological features of ALK-rearranged lung adenocarcinomas is helpful to identify cases that merit molecular testing. Design: We screened ALK rearrangements in 280 patients with lung adenocarcinomas diagnosed in 2008 to 2013 at our institution using Vysis dual color break-apart ALK probes. FISH was performed on paraffi n embedded tissue sections from cytologic and surgical specimens. Results: ALK rearrangement was seen in 6 males and 10 females (16/280 or 5.7%).
The median age of patients in our cohort was 54 years (range 29-85 years). All except one of our 16 patients were caucasian. Four patients were smokers, 2 were minimal smokers and 10 were never-smokers. Majority of the patients presented with stage 4 disease (12/16). Mean tumor size was 3cm (1 to 6.9 cm, SD 1.9). Only two patients underwent resection of the primary tumor. Most of our patients (13/16) had invasive adenocarcinoma with predominant solid type pattern. The most common cytological features were presence of signet ring (6/16) and pleomorphic (6/16) tumor cells. TTF-1 positivity was seen in 13 of 14 cases. Seven of 16 patients developed multiple brain metastases. The percentage of cells with abnormal FISH signals ranged from 19% to 93%. Median follow up duration for our cohort was 15 months (range 0 -92 months). One patient had concurrent KRAS mutation (G12C) in pre-crizotinib specimen. Ten of sixteen patients received crizotinib. Patients with ALK rearrangements receiving crizotinib had a signifi cantly higher survival (median survival 25 months with crizotinib versus median survival 10 months without crizotinib; p=0.017, log rank). Conclusions: Compared to previous studies of patients with ALK gene rearrangements, the patients in our cohort were older and more likely to be caucasian females who were never smokers. The predominant morphology was solid pattern, and the most common cytology was that of signet ring cell. Recognizing patients with ALK-rearranged lung adenocarcinoma who should receive crizotinib resulted in improved survival among our patient cohort, compared with those who received conventional chemotherapy. representative whole tissue sections were selected for immunohistochemical studies using antibodies directed against S-100, CD1a, fascin, CD3, CD4, CD8, CD20, CD99, kappa and lambda. The distribution of the lymphoid elements as well as clonality were assessed and recorded. Results: The patients were male with an age range from 21 to 33 years. Symptoms included cough, dyspnea and chest pain. All patients underwent thymectomy. Macroscopically, all tumors had a fl eshy, lobulated cut surface. Histologically, the tumors were composed of round to polygonal cells with indistinct cell borders, clear cytoplasm and prominent nucleoli. All tumors were accompanied by small lymphocytes infi ltrating fi brovascular septa and 3 showed granuloma formation. Striking follicular hyperplasia was evident in all cases, with tumor interspersed between prominent follicles with germinal centers. While these germinal centers were largely composed of mature B lymphocytes, mature T lymphocytes were the predominant cell component of the interfollicular areas. Immature T cells were not identifi ed. Scattered Langerhans cells were noted in between tumor cells and dendritic cells were seen in the mantle zones. All cases failed to show light chain restriction. Clinically, 3 patient received adjuvant chemotherapy. Follow-up showed that all patients were alive 12 to 48 months after diagnosis.
Conclusions:
In addition to cystic changes, thymic seminomas can be associated with striking lymphoid follicular hyperplasia to a degree whereby the tumor may be masked by the lymphoid component. The lymphoid infi ltrate is composed of a mix of mature B and T cells of a polyclonal nature. Familiarity with the possibility of thymic seminoma associated with fl orid follicular hyperplasia is important in order not to misdiagnose these cases for pure thymic follicular hyperplasia, which would require a different treatment approach. Background: Paragangliomas and primary carcinoid tumors of the mediastinum are lesions that belong to the neuroendocrine family of neoplasms. These tumors can share signifi cant histological and immunohistochemical overlap. Correct diagnosis, however, is of utmost importance as paragangliomas most often run a benign clinical course whereas primary carcinoid tumors of the mediastinum exhibit more aggressive biologic behavior. To this end, we performed a comparative immunohistochemical analysis using traditional and novel markers in 22 cases of paraganglioma and 24 cases of primary mediastinal carcinoid tumors. Design: Twenty-two cases of paraganglioma and 24 cases of primary mediastinal carcinoid tumors were reviewed and representative whole tissue sections were selected for immunohistochemical studies using antibodies directed against pancytokeratin (OSCAR), thyroid transcription factor-1 (TTF-1), napsin A, chromogranin A, synaptophysin and GATA-3. The percentage of positive tumor cells as well as the intensity of staining were evaluated and scored and the results compared between the two tumor types.
Results: All cases of paraganglioma were positive for chromogranin A and synaptophysin and negative for pancytokeratin, TTF-1 and napsin A. GATA-3 showed expression in 12/22 tumors (55%). Contrary to that, the carcinoid tumors were uniformely positive for pancytokeratin, and negative for napsin A and GATA-3. Synaptophysin and chromogranin A were expressed in 79% of cases, respectively. TTF-1 was positive in 4/24 of the carcinoid tumors (17%). Conclusions: Although pancytokeratin is confi rmed to be the single most useful marker in the separation of paragangliomas from primary mediastinal carcinoid tumors, two other markers are shown to be useful antibodies in this context. GATA-3, a novel marker commonly used in the diagnosis of breast and urothelial cell carcinomas, was shown to be expressed in 55% of paragangliomas but none of the carcinoid tumors. Reversely, TTF-1 can be positive in up to 17% of primary mediastinal carcinoid tumors but was not identifi ed in any of the paragangliomas. Background: Targeted therapy of activating EGFR mutations in lung adenocarcinomas with tyrosine kinase inhibitors (TKI) results in decreased tumor burden that is often a transient response due to the presumed outgrowth of TKI resistant clones. c-Met amplifi cation accounts for 5-20% of EGFR TKI resistance. Cytogenetic methods are traditionally used to detect c-Met amplifi cation. However, immunohistochemistry (IHC) offers a cost-effective alternative or adjunctive method for detection. We compared c-Met IHC to fl uorescence in-situ hybridization (FISH) as the gold standard. Design: Five micron sections of 18 cases with c-Met FISH assays were immunostained for c-Met monoclonal clone SP44 (1:100) (Spring BioScience, Pleasanton, CA). Results of expression and amplifi cation were compared. Results: In 18 adenocarcinoma cases, c-Met IHC identifi ed 100% of c-Met FISH amplifi ed tumors with 3+ staining in greater than 80% of tumor cells (n=2). 6 cases showed 2-3+ positive IHC but no amplifi cation was detected by FISH. 10 cases were negative for both IHC and FISH. False positives observed with IHC occurred only in cytologic specimens (n=6). One case produced positive c-Met IHC and negative FISH in a cytologic specimen, but was negative by IHC and FISH in the resection specimen of the same lesion.
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